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Abstract 
 
Inflammatory bowel disease is a chronic inflammatory disorder of the epithelium of the 
intestinal tract caused by multiple factors and for which therapeutic options are limited. 
IBD is an idiopathic disease and the exact cause remains unknown. Patients with IBD 
have increased intestinal permeability, barrier disfunction of the epithelium and 
cumulative exposure to antigens leading to activation of the immune system, 
production of pro-inflammatory cytokines and reactive oxygen species resultant in 
intestinal mucosa lesions. The treatment currently used to IBD requires a long-term 
pharmacological approach based on the combination of drugs that have anti-
inflammatory activity and allows the inhibition of the initial events of inflammation, 
however consist only of symptomatic and palliative treatments and are unable to 
maintain remission of inflammation in the colon for long periods of time. Experimental 
models of IBD supply considerable information on the pathogenesis of this illness and 
represent an important tool in testing new strategies of treatment, since they mimic the 
features of the disease. The main aim of this project is to develop a preliminary study 
towards a novel chronic experimental model to study IBD in order to support a future 
new model of chronic induced colitis in rodents using TNBS. The experimental model 
with TNBS consists in the induction of intestinal inflammation by a chemical process 
through intracolonic administration of TNBS. The mice were evaluated taking into 
account parameters such as body weight, stool consistency, anus appearance and 
colon length and biochemical markers such as ALP, urea, creatinine, ALT, fecal 
hemoglobin, TNF-α, IL-10 and histopathological score. TNBS-induced chronic colitis 
was tested in 6 weeks, with weekly TNBS instillations, providing a chronic intestinal 
inflammation model. The TNBS groups showed a slight change in intestinal motility 
characterized by diarrhea, anus edema and moderate morbidity, while the control 
groups remained unchanged. These mice also showed a slight and progressive 
increase in body weight, a reduced colon length, and an increase in fecal hemoglobin 
concentration, which was maintained until the end of the experimental protocol. Colitic 
mice presented raised values of ALP, TNF-α and fecal hemoglobin after week 4 until 
the end of the experiment, and contrary to expected increase values of an anti-
inflammatory cytokine, IL-10. These results are consistent with the correct induction of 
experimental chronic colitis by TNBS. These preliminary data allow suggesting that 
TNBS-induced chronic colitis should be developed in 4 weeks, providing a chronic 
intestinal inflammation model. 
 
 
 
 
 
 
 
 
Key-Words: Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, TNBS- 
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Resumo 
 
 A doença inflamatória intestinal (DII) é uma desordem inflamatória crónica do epitélio 
do trato intestinal causada por múltiplos fatores e para os quais as opções terapêuticas 
são limitadas [1,2].  A DII é uma doença idiopática na qual a causa exata permanece 
desconhecida [3].  Os pacientes com DII apresentam permeabilidade intestinal 
aumentada, disfunção da barreira do epitélio e exposição cumulativa a antigénios que 
levam à ativação do sistema imunitário, produção de citocinas pro-inflamatórias e 
espécies reativas de oxigénio resultando em lesões da mucosa intestinal [4].  O 
tratamento atualmente utilizado para DII requer uma abordagem farmacológica de 
longo prazo baseada na combinação de drogas que têm atividade anti-inflamatória e 
permite a inibição dos eventos iniciais de inflamação, no entanto consiste apenas em 
tratamentos sintomáticos e paliativos que são incapazes de manter a remissão da 
inflamação no cólon por longos períodos de tempo [4,5]. Os modelos experimentais de 
doença inflamatória intestinal fornecem informações consideráveis sobre a patogénese 
da doença e representam uma ferramenta importante no teste de novas estratégias de 
tratamento [6,7]. O principal objetivo deste projeto é desenvolver um estudo preliminar 
em direção a um novo modelo experimental crónico para estudar a DII, a fim de apoiar 
um futuro modelo de colite crónica em roedores com TNBS. O novo modelo 
experimental de colite crónica deve ser capaz de simular a doença inflamatória 
intestinal em humanos, para posterior estudo das vias metabólicas envolvidas na DII e 
futura modulação farmacológica com o objetivo de melhorar os tratamentos para DII 
atualmente conhecidos.  
 
O modelo experimental com TNBS consiste na indução de inflamação intestinal por 
um processo químico através da administração intracolónica de TNBS como descrito 
pelo método de Morris [8]. Utilizou-se murganhos CD-1 de 6-10 semanas de idade e 
com 25-40g de peso. Os grupos experimentais foram estruturados de acordo com o 
principal objetivo do estudo. Foram ainda formados grupos de controlo para servirem 
de referência na comparação dos resultados com os grupos em estudo. No final do 
período experimental, os ratos foram anestesiados e foram recolhidas amostras de 
sangue por punção cardíaca. Em seguida, os murganhos foram sacrificados por 
deslocação cervical e necropsiados. Os murganhos foram avaliados tendo em conta 
sinais clínicos como peso corporal, consistência das fezes, aparência do ânus e 
comprimento do cólon e marcadores bioquímicos como ALP, ureia, creatinina, ALT, 
hemoglobina fecal avaliados através do método automático ADVIA e TNF-α e IL-10 
determinados por ELISA. O score histopatológico final será avaliado com base na 
gravidade e extensão das lesões segundo os critérios adaptados de Corazza e 
colegas [9] e Seamons e colegas [10]. As seções histopatológicas serão examinadas e 
pontuadas de acordo com a presença de inflamação (0-4 de gravidade crescente) com 
alguns parâmetros, a saber: (1) presença de perda / necrose tecidual, (2) gravidade da 
lesão epitelial da mucosa, (3) inflamação, ( 4) extensão 1 - a percentagem de intestino 
afetado de qualquer maneira e (5) extensão 2 - a percentagem de intestino afetado 
pela lesão mais grave. A gravidade da colite foi calculada somando as lesões 
individuais e os scores de extensão, promovendo um score final de colite (score 
máximo = 20). 
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O principal objetivo é o desenvolvimento e padronização do modelo de colite crónica 
induzida por TNBS, uma vez que a evolução de parâmetros associados a infeção 
crónica como da lesão intestinal mais grave causada pelo TNBS ocorrem 
gradualmente após uma semana de indução com durabilidade de até 8 semanas e os 
protocolos do modelo de colite induzida por TNBS não são padronizados [8,11,12]. 
Seis grupos independentes de colite induzida por TNBS em murganhos foram então 
monitorizados sob as mesmas condições específicas durante 6 semanas. Os grupos 
foram induzidos semanalmente e sacrificados no dia 7 de cada semana, dependendo 
do grupo experimental, a fim de se obter um modelo crónico de colite induzida por 
TNBS. O objetivo era identificar em que período de tempo o padrão de lesão crónica 
intestinal máxima se mantinha, pelo método de indução usado no presente estudo. 
Relativamente aos resultados obtidos nesta experiência, verificou-se que o modelo 
crónico preliminar de colite induzida por TNBS desenvolveu-se a partir da quarta 
semana de indução. O grupo TNBS apresentou uma leve alteração da motilidade 
intestinal caracterizada por diarreia, edema do ânus e morbilidade moderada, 
enquanto os grupos controlo permaneceram sem alterações. Estes murganhos 
apresentaram ainda um aumento leve e progressivo do peso corporal, um 
comprimento do cólon reduzido e um aumento da concentração de hemoglobina fecal, 
que se mantém até ao final do protocolo experimental. A indução de colite por TNBS 
promoveu, ao fim de 4 semanas, um aumento dos mediadores inflamatórios, tais 
como, TNF-α, e contrariamente ao esperado aumento da uma citocina anti-
inflamatória, IL-10, bem como a manutenção destes valores até ao final do período 
experimental. Estes resultados são consistentes com a indução correta de colite 
crónica experimental por TNBS. 
 
Em conclusão, a validação desse modelo animal é realmente relevante para a 
comunidade científica, pois, até á data, não existe prática padronizada na indução de 
colite por TNBS e a utilização deste modelo em futura modulação farmacológica pode 
facilitar um tratamento mais eficaz e seletivo do que o atualmente conhecido. 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: Doenças Inflamatórias Intestinais, Doença de Crohn, Colite 
Ulcerativa, Colite induzida por TNBS, Modelo animal 
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Introduction 
 
 
Inflammatory bowel disease (IBD) is a common chronic inflammatory disease of the 
gastro-intestinal tract characterized by chronic inflammation of the intestinal epithelium, 
bowels ulceration and damaging mucosal tissues, resulting in symptoms of diarrhea, 
weight loss and abdominal pain [1,2]. IBD results from inappropriate and uncontrolled 
immune responses driven by the luminal flora in genetically susceptible individuals. 
Crohn's disease (CD) and Ulcerative colitis (UC) are the two major forms of IBD and 
can be distinguished by the location of inflammation within the gastrointestinal tract [5]. 
These disorders present similarity, however, they are distinguished by the different 
pathophysiological aspects and clinical manifestations [4]. CD presents transmural 
inflammation in the entire length of the GI tract, although it predominantly affects the 
region adjacent to the ileum and cecum [13]. Typically presents in a discontinuous 
manner, affecting several proportions of the gastrointestinal tract and associated with 
complications such as fistulas, stenosis and abscesses [14]. In contrast, UC patients, 
inflammation usually involves the rectum and extends contiguously in the colon by a 
variable degree affecting only the superficial mucosa [14]. 
 
The IBD is a chronic and intermittent disease, during relapses, symptoms severity 
varies between slight to severe and during remissions the symptoms can even diminish 
or disappear. Generally, symptoms depend on the intestinal affected segment and 
usually include diarrhea often with blood, colic abdominal pain and fecal urgency. 
Beyond these, other unspecific symptoms may occur like fever, loss of appetite and 
weight, fatigue and primary amenorrhea [15]. 
 
Immunologically patients with IBD have continuously activated innate and acquired 
immune system with increased recruitment and retention of effector macrophages, 
neutrophils, T and B cell in the local inflammation where they are activated, release 
pro-inflammatory cytokines, and loss of tolerance to enteric commensal bacteria. The 
higher recruitment as well as prolonged survival of effector cells caused by decreased 
cellular apoptosis exacerbate the immune response and promote the accumulation of 
effector cells in local intestinal area [16]. Thus, pathogenesis of inflammatory bowel 
disease is not completely understood but, it is well accepted that abnormal mucosal 
immune response, microbial factors and epithelial cell abnormalities can facilitate this 
response [17]. 
 
Otherwise, the histologic involvement of lymphocytes T helper CD4 is observed in both 
subtypes of IBD, however the pro-inflammatory cytokines responsible for the 
establishment and development of pathology are different [4]. The inflammatory 
response in CD is mediated by lymphocytes Th1 and Th17 with high levels of 
interleukin 12 (IL-12), interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-
α) [3,4,16]. By his side, UC inflammatory response is atypically unleashed by 
lymphocytes Th2, increasing interleukins 4 and 5 and granulocyte macrophage colony 
stimulating factor. 
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The IBD has been revealed a world health problem with growing incidence, particularly 
in subjects with 15 to 30 years old [4]. The IBD has increased incidence in Portugal, 
currently affecting around 7000 to 15000 Portuguese [18].  Statistical data show a 
marked increase in the countries of the southern hemisphere, although it is still more 
prevalent in north hemisphere countries, which can be justified by the lifestyle 
westernization of habitants from poorest countries [4]. Specifically, the hygiene 
hypothesis reveals that persons less exposed in childhood to infections or unsanitary 
conditions lose commensal organisms or organisms that regulates T cell development, 
or instead do not develop a sufficient immune repertoire once they were not exposed to 
necessary noxious organisms. Such individuals are associated with a higher incidence 
of chronic immune diseases, including inflammatory bowel disease [19,20,21]. 
 
The etiology of IBD remains undefined, but it is well accepted that IBD is multifactorial, 
involving interactions between host immune system, genetic susceptibility and 
responses to environmental and microbial factors [17].  Genetic and environmental 
factors, immune system dysregulation, modification of luminal bacteria and the 
increase of intestinal permeability, have a crucial role in the dysregulation of intestinal 
immunity, origin gastrointestinal injury. [7,22] Four genes have been associated with 
Crohn’s disease, CARD15, SLC22A4/5, DLG5, PPARG and one with ulcerative colitis, 
MDR1, it is suggested that these genes regulate several important biologic functions, 
including immune regulation, mucosal barrier integrity and microbial homeostasis 
[7,16]. Several environmental factors like smoking, diet, the use of antibiotics and non-
steroidal anti-inflammatory drugs, stress and infection are proposed as possible cause 
in the pathogenesis of inflammatory bowel disease [16,23,24]. These factors trigger in 
patients with IBD increased intestinal permeability, which leads to a decrease in the 
barrier function of the epithelium, allowing greater exposure to antigens and 
consequent activation of the immune system and pro-inflammatory cytokines raising 
inflammation [16].  
 
The diagnostic of CD and UC includes clinical characteristics, laboratorial tests like 
complete blood count, sedimentation rate, biochemical analyzes such as c-reactive 
protein, ferritin, serum albumin, fecal occult blood test and stool culture to mislead 
infections caused by microorganisms. More specifically, is used Anti-Saccharomyces 
cerevisiae antibodies (ASCA) and Perinuclear Anti-Neutrophil Cytoplasmic Antibodies 
(p-ANCA) which allow diagnostic precision in complex cases and distinguish CD from 
UC. Besides that, abdominal X-ray, colonoscopy, endoscopy and biopsy should be 
done. [1] 
 
The treatment of IBD often requires a long-term pharmacological approach based on 
the combination of drugs to control acute reactions, maintain remission and treat 
specific complications. Actually, therapeutics to the treatment of IBD include a large 
number of drugs, like aminosalicylates, glucocorticoids, immunosuppressants, 
immunomodulators and biologic therapy, which have little selectivity for IBD [4,5]. The 
majority of therapeutics have anti-inflammatory activity that allows the inhibition of the 
initial events of inflammation with the migration of inflammatory mediators, vasodilation, 
vascular permeability and leukocyte infiltration. These drugs also act decreasing 
macrophages recruitment, inhibit the production of IL-1 by monocytes, IL-2 and TNF-α 
by lymphocytes, phospholipase A2, prostaglandins and leukotrienes [4,5]. 
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Unfortunately, the therapeutic options available today do not bring alive the cure to IBD 
and the accessible treatments have serious side effects and high cost, besides that, 
there are patients who do not respond to any of the treatments, aspects that greatly 
limit its use [5] 
 
Nowadays IBD treatments introduce risks to patients, do not represent the cure for the 
disease, consist only of symptomatic and palliative treatments and are unable to 
maintain remission of inflammation in the colon for long periods of time, indicating the 
urgent need to search for new products with intestinal anti-inflammatory activity for cure 
or prevent this disease [1,5]. 
 
In our research group, we have tested several new pharmacological approaches with 
benefits in this field [25-30], in this sense it is extremely important clarify the 
inflammatory process related with this pathology to propose new strategies to modulate 
inflammatory response, different from those already known, to treat effectively IBD and 
carrying out further studies in this and other areas that may solve many of the puzzles 
that mark this pathology. 
 
With this project we propose to develop a preliminary study towards a novel chronic 
experimental model to study IBD, able to mimic inflammatory bowel disease in 
humans, for posterior study metabolic pathways involved in IBD and future 
pharmacological modulation. Thus, this thesis was divided into two chapters of 
literature review, one chapter of methodology, one chapter of presentation and 
discussion of results related to the development of the model, one chapter of the final 
discussion and main conclusions and, finally, one last chapter of the references. 
Therefore: 
- Chapter I: state of the art description of inflammatory bowel disease, including 
its classification, diagnosis, as well as pharmacological treatment currently 
recommended; 
- Chapter II: relevance of studies in animal models, presentation of existing 
animal models of experimental colitis and characterization of the chemically induced 
model of colitis used in this experimental work; 
- Chapter III: description of the used methodology, such as the induction 
method, 
experimental groups, evaluated parameters and statistical tests; 
- Chapter IV: presentation of the results of the development of experimental 
colitis induced by TNBS; 
- Chapter V: discussion of the development of experimental colitis induced by 
TNBS; 
- Chapter VI: synthesis, discussion and the main conclusions of the work, as 
well as future prospects; 
- Chapter VII: all references used in the development of the thesis. 
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Aim 
 
The main aim of this project is to develop a preliminary study towards a novel 
chronic experimental model to study IBD in order to support a future new model of 
chronic induced colitis in rodents using TNBS. The model should be able to mimic 
inflammatory bowel disease in humans, for posterior test a set of drugs that modulate 
some important metabolic pathways in the establishment and development of 
inflammation in IBD.  
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Chapter 1 - Inflammatory Bowel Disease 
1. Definition  
 
IBD is a chronic, idiopathic, and relapsing inflammatory disease that affect the 
gastrointestinal tract through a cascade of inflammatory reactions that culminate in an 
immune system response. IBD is characterized by chronic inflammation of the 
intestinal epithelium, bowels ulceration and damaging mucosal tissues, resulting in 
symptoms like diarrhea, weight loss and abdominal pain [1,2].  
 
 
 
Figure 1. Ulcerative Colitis vs Crohn´s Disease [adapted from site QuIBD.com] 
 
UC and CD are the two major forms of IBD, have different pathological and clinical 
characteristics, in which they differ in the extent and distribution of inflammation in the 
gastrointestinal tract and in the depth of involvement of the intestinal wall (Figure 1) 
[4,5]. Ulcerative colitis is a recurrent chronic ulcer inflammatory disorder that begins in 
the rectum and extends contiguously along the colon in the retrograde direction with 
inflammatory involvement by a variable degree affecting the inner layer of the mucosa, 
with diffuse and uniform inflammation. It is a disease in continuity and has as 
characteristics the presence of abdominal pain and episodes of bloody mucoid 
diarrhea. The course of UC is characterized by symptomatic periods interspersed with 
periods of remission [31,32]. 
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In contrast, the CD lesions are distributed in a non-confluent pattern, presenting 
transmural inflammation, reaching all layers of the digestive wall. This disease can 
affect the entire length of the GI tract, from the mouth to the anus, although it 
predominantly affects the region adjacent to the ileum and cecum, altering the entire 
intestinal integrity [13,33,34]. The progression of the disease is usually characterized 
by episodes of exacerbation and remission of variable duration. The clinical 
presentation will depend on the location of the disease, including diarrhea, abdominal 
pain, fever, signs of intestinal obstruction, presence of blood and mucus in the feces 
and perianal lesions. CD is associated with complications such as fistulas, stenosis, 
abscesses and intestinal obstruction (Table 1) [35-37].  
 
A third classification of IBD, IBD unclassified or indeterminate colitis, can be used when 
a distinction in diagnosis of UC and CD cannot be made through clinical signs and 
when all diagnostic exams where take in consideration. However, indeterminate colitis 
only represents a minority of cases of IBD, thus allowing in the majority of cases  
monitoring and treatment of the disease [34]. 
 
Table 1. Differences between Crohn´s disease and ulcerative colitis 
[adapted from MSD Professional Edition Manuals, 2019] 
 
Crohn's Disease 
 
Ulcerative Colitis 
 
Small intestine involved in 80% of the time. Disease is confined to the colon. 
Retossigmoid is generally spared; the colonic 
involvement is usually on the right side. 
Retosigmoid is invariably affected; the colonic 
involvement is generally on the left. 
Severe rectal bleeding is uncommon, except 
in 75 to 85% of cases of Crohn's colitis. Significant rectal bleeding is always gift. 
Fistulas, masses, and abscesses are 
common. 
No fistulas occur. 
 
Perianal lesions are significant in 25 to 35% of 
cases. No significant perianal lesions ever occur. 
In radiographs, the intestinal wall is 
asymmetrically affected and in a segmental 
way, with areas spared between segments 
affected. 
The intestinal wall is affected symmetrically 
and of the proximal rectum. 
The endoscopic appearance is irregular, with 
discrete ulcerations separated by segments of 
normal-appearing mucosa. 
The inflammation is uniform and diffuse. 
Microscopic inflammation and fissures 
transmural; the distribution of lesions is 
usually highly focal. 
Inflammation is restricted to the mucosa, 
except in severe cases. 
Epithelioid granulomas (sarcoidosis type) are 
detected in the intestinal wall or lymph nodes 
in 25 to 50% of cases (pathognomonic). 
No typical epithelial granulomas occur. 
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1.1 Classification 
 
The current IBD classification, known as the Montreal Classification, resulted from the 
review of the Vienna classification, permits characterizes the clinical features of this 
disorders as well as, clarify the diagnosis of CD an UC [38,39].   
 
 
The Montreal classification, regarding CD, considers 3 parameters, age of onset (A), 
location of disease (L) and disease behavior (B). The presentation of CD is highly 
variable. A single episode may not be followed by further episodes or the patient may 
experience continuous, unremitting disease (Table 2) [38,39].   
   
 
Table 2. Montreal classification of Crohn`s disease 
[adapted from Satsangi et al., 2006] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since there is an inherent subjectivity to symptoms that may condition the evaluation of 
CD activity, there are several indices which are used as an aid in identifying the phase 
of the pathology. An additional tool, known as CDAI (Crohn's disease activity index), 
should be considered in patients with CD. CDAI is not a classification of CD but 
represents a numerical estimate of the interpretation of the patient's symptoms, 
allowing to define the severity of disease activity. The CDAI calculation is the sum of 
the products of a list of eight items, multiplied by weighting factors, the total of which 
defines the severity of disease activity. Thus, CD activity can be classified as mild to 
moderate, moderate to severe and severe to fulminant. Total values less than or equal 
to 150 are associated with quiescent or remission. Values above 150 are indicative of 
active disease, if greater than 450 allow the classification of extremely severe disease 
(Table 3) [34,40].  
 
 
AGE AT DIAGNOSIS 
A1 < 16 years 
A2 17 - 40 years 
A3 > 40 years 
   
LOCATION 
L1 Ileal 
L2 Colonic 
L3 Ileocolonic 
L4 Isolated upper disease 
   
 
BEHAVIOUR 
B1 Non-stricturing, non-penetrating 
B2 Stricturing 
B3 Penetrating 
P Perianal disease modifier** 
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Table 3. Grading of disease activity in Crohn´s disease  
[adapted from Dignass et al., 2012] 
Legend: CDAI - Crohn’s Disease Activity Index; BMI - Body mass index; CRP - C reactive protein. 
 
The typical follow-up of UC consists in periods of exacerbation alternating with periods 
of symptomatic remission. The determination of the clinical picture and subsequent 
individualization of the therapy depend of two factors: extent and severity of 
inflammation. The Montreal classification, relative to UC, assessed the disease 
according this two parameters, severity and extension. [38,39]. 
 
The Montreal classification of disease extent of UC allows extent to be defined into 
three subgroups (Table 4), according to the maximal extent of inflammation observed at 
colonoscopy. Extension can be divided into proctitis when only the rectum is inflamed, 
distal when the affected extension is up to the splenic, encompassing proctitis when it 
extends beyond the splenic angle not reaching the blind and pancolitis when it reaches 
the full extent to the blind [39]. 
 
 
Table 4. Montreal classification for ulcerative colitis extent  
[adapted from Satsangi et al., 2006] 
Extent Anatomy 
Ulcerative proctitis 
Involvement limited to the 
rectum (that is, proximal 
extent of 
inflammation is distal to the 
rectosigmoid junction) 
Left sided UC (distal UC) 
Involvement limited to a 
proportion of the colorectum 
distal to the splenic flexure 
Extensive UC (pancolitis) 
Involvement extends 
proximal to the splenic 
flexure 
Legend: UC – Ulcerative colitis. 
 
 
Mild 
CDAI of 150 – 220 
(eg. ambulatory, eating and 
drinking, < 10% weight 
loss) 
No features of obstruction, 
fever, dehydration, 
abdominal 
mass or tenderness 
CRP increased 
above the 
upper limit of normal 
Moderate 
CDAI of 220 – 450 
(eg. intermittent vomiting or 
weight loss > 10%) 
Treatment for mild disease 
ineffective or tender mass. 
No overt obstruction 
CRP elevated above 
the 
upper limit of normal 
Severe 
CDAI > 450 (eg. cachexia 
(BMI < 18 Kg m-2 ) or 
evidence of obstruction or 
abscess) 
Persistent symptoms 
despite 
intensive treatment 
CRP increased 
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UC is an intermittent and relapsing disease where patients experience periods with no 
symptoms, which makes diagnosis difficult since the symptoms are not sufficiently clear 
[31,32,41]. Hereupon, the Montreal classification also classified the UC severity as 
mild, moderate and severe and fulminant determined by clinical signs and symptoms 
(Table 5) [38]. The arbitrary distinction between the different classifications are 
determined by the clinical signs and symptoms and are, generally, clinical 
recommendations for therapeutic decision-making. 
 
 
Table 5. Montreal classification for ulcerative colitis severity  
[adapted from Satsangi et al., 2006] 
 
Legend: ESR - Erythrocyte sedimentation rate; CRP - C reactive protein. 
 
 
1.2 Epidemiology 
 
The inflammatory bowel disease is a chronic disease that affects approximately 3 
million people in Europe and has been revealed a world health problem with growing 
incidence [42]. IBD affects individuals of any age, however, it has two peaks of greater 
incidence, a first between 15 and 30 years and a second between 50 and 70 years 
[14,43] The annual healthcare costs were estimated at around 4.5–5.6 billion euros, in 
Europe, and 6.3 billion dollars, in the United States of America [44].   
 
In the past, it was an uncommon condition, increasing its incidence in the developed 
countries, in particular in the Europe, Australia, New Zealand and North America, 
where it is estimated that its prevalence practically double over the next decade. The 
distribution of the disease has undergone changes, in particular in the over last 20 
years, and has also expanded to developing countries [44]. 
 
Statistical data show a marked increase in the countries of the southern hemisphere, 
although it is still more prevalent in north hemisphere countries, which can be justified 
by the lifestyle westernization of habitants from poorest countries [4,45]. The hygiene 
hypothesis, a hypothetical explanation to this data, suggests that persons less exposed 
in childhood to infections or unhygienic conditions lose commensal organisms or 
organisms that regulates T cell development, or yet do not develop a sufficient immune 
repertoire once they were not exposed to essential harmful organisms, propose a 
higher incidence of chronic immune diseases, including inflammatory bowel disease, 
for that individuals [19-21]. These results may vary according to the study carried out, 
 Mild Moderate Severe 
BLOODY 
STOOLS/DAY 
< 4  4 or more if  ≥ 6 and 
PULSE < 90 bpm ≤ 90 bpm > 90 bpm or 
TEMPERATURE < 37.5˚C  ≤ 37.8˚C  > 37.8˚C or 
HAEMOGLOBIN > 11.5 g/dl  ≥ 10.5 g/dl  < 10.5 g/dl or 
ESR < 20 mm/h  ≤ 30 mm/h  > 30 mm/h or 
CRP Normal  ≤ 30 mg/L  > 30 mg/L 
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since the epidemiological of IBD is limited due to the difficulty in carrying out population 
studies, the non-use of universally accepted diagnostic criteria and the scarcity of 
registries. However, it is notorious that the incidence of IBD has increased worldwide 
[18]. 
 
In Portugal, the IBD incidence has increased, currently affecting around 7000 to 15000 
Portuguese however, epidemiological data are scarce, which does not allow the 
incidence and prevalence of IBD in our country over time. One study conducted 
between 2003 and 2007, which assessed the prevalence of IBD in Portugal, states that 
there was an increase from 86 to 146 per 100,000 people and that this increase was 
homogeneous in all districts of the country. The prevalence of UC and CD is similar, as 
his distribution pattern by age and sex, although female prevalence is slightly higher 
than the male sex. Particularly the districts of Lisbon and Porto were the most affected 
with the disease [18,44]. Furthermore, hospitalization rates have increased by 33% and 
13%, concerning CD and UC patients, respectively, from 2000 to 2015 [44]. 
  
1.3 Etiology 
 
The etiology of IBD remains undefined, but it is well accepted that IBD is multifactorial, 
involving interactions between host immune system, genetic susceptibility and 
responses to environmental and microbial factors. None of the factors alone is 
sufficient to the development of the disease [7,22]. Thus, the interaction between 
genetic susceptibility and an abnormal immune response with deregulation of the 
innate and adaptive immune response and commitment of the function of the epithelial 
barrier are the main cause to IBD (Figure 2) [14]. 
  1.3.1 Environmental factors 
 
Several environmental factors like smoking, diet, the use of antibiotics and non-
steroidal anti-inflammatory drugs, stress and infection are proposed as possible cause 
in the pathogenesis of inflammatory bowel disease [16,23,24]. These factors trigger in 
patients with IBD increased intestinal permeability, which leads to a decrease in the 
barrier function of the epithelium, allowing greater exposure to antigens and 
consequent activation of the immune system and pro-inflammatory cytokines, raising 
inflammation, how-ever the mechanism on which this factors act promising the disease 
is not yet known [16]. 
 
IBD has a higher incidence in industrialized countries proposed due to the 
westernization of its lifestyle. Regions like Eastern Europe and Asia, where this 
increase in IBD can be observed, have recently adopted westernized diets, like low-
fiber, high-sugar and high animal fat, suggesting the influence of diet in the 
development of the disease. Thus, it is logical to consider diet as a determinant factor 
in IBD since it is an enteric disease and it is known the ability of some foods to act as 
antigens promoting inflammation, such as alcohol, refined sugar and coffee and in turn 
others are preventive in the intestinal inflammatory process like fruits, vegetables and 
fibers, otherwise various data try to compose the relationship of IBD with a specific diet 
or food without success [46,47]. 
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Since it is more common in developed areas and there is currently an increase in non-
industrialized countries, has been developed a theory to explain the phenomenon, the 
hygiene hypothesis reveals that persons less exposed in childhood to infections or 
unsanitary conditions lose commensal organisms or organisms that regulates T cell 
development, or instead do not develop a sufficient immune repertoire, once they was 
not exposed to necessary noxious organisms, contributing to an immature immune 
system which causes an inappropriate immune response when exposure to noxious 
agents reoccurs [19,20]. 
 
Smoking is recognized as contributor to IBD, nicotine, carbon monoxide and hypoxia 
have all been suggested to be mediators of the effects of smoking on IBD [48-50]. 
However, smoking have different effects when it comes to CD and UC, if in turn the CD 
has an exacerbating effect on the disease in UC have an protective effect, 
nevertheless, there is still no explanation for this event [16]. CD patients who smoke 
tent to have more complications and more severe symptoms throughout the disease, 
indicative of detrimental effect on CD [47,51,52]. Contrary on UC smoking seems to 
have protective effect delay the beginning of disease and studies have shown that 
current smoking reduced the risk of UC [43,47]. 
Oral contraceptives and non-steroidal anti-inflammatory drugs are drugs studied as 
possible etiological factors with IBD. In the case of oral contraceptives their association 
with IBD is not yet fully known but it is believed that thrombogenic properties may be 
related to ischemia and changes in mucosal integrity and consequently allow the entry 
of antigens into the intestinal lumen [47]. Non-steroidal anti-inflammatory drugs in turn 
have a side effect causing injury in the gastrointestinal tract. There is an increase in 
vascular permeability and local lesion caused by these drugs and in addition a 
systemic effect on the prostaglandins, reducing the protection of the mucosa of the 
gastrointestinal tract causing alterations in the permeability of the colon membrane 
leading to the development of IBD [53].  
 
Nowadays various changes in human behavior have been associated with an increase 
in the incidence of IBD. This increase in countries that have been to adopt an 
industrialized lifestyle suggests that the environmental factors are crucial as triggers of 
disease. There are epidemiological data that appear to show a close correlation 
between the infectious diseases, vaccination and stress of the population with 
increasing incidence of autoimmune diseases and chronic inflammatory diseases, but 
so far without conclusive results [47]. 
1.3.2 Genetic factors 
 
Actually, there is evidence that different genetic factors, through different inflammatory 
mechanisms predispose to the development of IBD. The role of genetics in the 
pathogenesis of IBD was initially suggested in household and in twins, however there is 
no evidence of classic heredity. IBD is overlapping in both genders but occurrence of 
disease is suggested to be influenced by race and some specific ethnic groups 
[43,51,52]. 
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At least 201 loci were identified, most of them associated with both forms, indicating 
common mechanisms in both diseases, but specific to CD and specific UC. Despite the 
divergence in the effect in the immune system, putative genes can be divided into 
those that influence innate immunity, autophagy, the epithelial barrier, immune 
responses, adaptive responses to oxidative stress and antimicrobial [7,16].  
 
Four genes have been associated with Crohn’s disease, CARD15, SLC22A4/5, DLG5, 
PPARG and one with ulcerative colitis, MDR1, it is suggested that these genes regulate 
several important biologic functions, including immune regulation, mucosal barrier 
integrity and microbial homeostasis [7,16]. CARD15 localized at chromosome 16 
promotes NF-κB activation and regulation, killing of intracellular pathogens, paneth-cell 
function, α-defensin production and plays an important role in the innate immune 
response, apoptosis and recognition, conferring greater susceptibility to CD. 
SLC22A4/5 located at 5 chromosome has as function organic cation, carnitine 
transporters, possibly transport xenobiotic substances. The gene DLG5 in 10 
chromosome is an epithelial scaffolding protein and PPARγ in chromosome 3 acts as 
an intracellular inhibitor of NF-κB and in cellular activation, lastly MDR1 located at 7 
chromosome is an efflux transporter for drugs and, possibly, xenobiotic compounds. 
Other genes involved in the autogenic innate immune system, such as ATG16L1, 
IRGM and LRRK, and the genes involved in adaptive immunity, such as IL23R, IL12B 
and STAT3, are strongly associated with CD and possibly UC [7,16]. 
 
Genetic factors play a significant role in predisposition to IBD once increase 
susceptibility to IBD but also influence the degree of severity and extension of 
pathology. Genetic factors may be important for the understanding of the disease as 
well as the association of these with changes in the intestinal immune system are 
critical points for the knowledge of the physiology of the disease and for the 
development of new drugs [7,16]. 
 
1.3.3 Immunological Factors 
 
The intestinal immune system is one of the largest and most complex of the human 
body, protects from the entry of pathogens and is essential for the maintenance of 
physiology and prevention of infections. The intestinal immune system is exposed to 
large numbers of antigens however is well coordinated to prevent the entry of harmful 
and pathogenic agents and does not react against commensal bacteria and antigens 
from the diet. The intestinal mucosa has a specialized defense system that is divided 
immune and not immune due to the constant exposure to pathogens and the ability to 
recognize harmful agents [47].   
 
But when a reaction occurs against non-pathogenic particles and breaking this 
homeostasis inflammatory disturbances such as IBD may occur. Patients with IBD have 
continuously activated innate and acquired immune system with increased recruitment 
and retention of effector macrophages, neutrophils, T and B cell in the local 
inflammation where they are activated, release pro-inflammatory cytokines, and loss of 
tolerance to enteric commensal bacteria [14]. The higher recruitment as well as 
prolonged survival of effector cells caused by decreased cellular apoptosis exacerbate 
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the immune response and promote the accumulation of effector cells in local intestinal 
area, raising continuously uncontrolled inflammation [16]. 
 
1.3.4 Microbial Factors 
 
The intestinal microbiota is a crucial factor in the development of IBD, the enteric 
bacteria and their production are involved in the triggering and perpetuation of the 
disease. The mechanism by which bacteria lead to the development of disease relates 
to increased site permeability and triggering of the immune response. Various 
microorganisms are related to the development of IBD as Mycobacterium 
paratuberculosis, Listeria monocytogenes, Chlamydia trachomatis and Escherichia coli 
[43]. The balance between beneficial bacteria and pathogenic species determines 
intestinal homeostasis and this balance can be manipulated by different drugs for the 
treatment and prevention of recurrences of IBD. The intestinal microbiome is the 
largest reservoir of microorganisms in the human body, having extremely useful 
functions, namely digestive, immune system education and repression of the growth of 
harmful microorganisms. The dysbiosis in IBD translates into a change in microbioma 
composition, diversity and quantity, microbiological changes present in both forms of 
IBD [47].  
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Figure 2. Conceptual framework for the pathogenesis of IBD  
[adapted from Neurath, 2014] 
Legend: NSAID - Non-steroidal anti-inflammatory drugs; Treg cell - Regulatory T cells. 
 
1.4 Pathogenesis 
 
Actually, is known that IBD is characterized by an atypical mucosal immune response 
and that various factors can enable this response but still not exist a defined origin to 
pathogenesis of IBD. However there are two different theories taking into account the 
awakening of the disease, the first proposes an initial dysregulation of the mucosal 
immune system that takes to exacerbated immunologic responses, in turn the other 
concept values that changes in the composition of bowel microflora associated with 
disturbed epithelial barrier function cause pathologic responses from the normal 
mucosal immune system (Figure 3) [17]. 
 
Phenotypically IBD patients have activated innate and acquired immune responses 
with accumulation of high levels of macrophages, neutrophils and T and B cells 
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recruitment in the inflamed bowel with production of pro-inflammatory cytokines and 
loss of tolerance to enteric commensal bacteria [16]. The enhanced recruitment as well 
as prolonged survival caused by decreased cellular apoptosis contribute to the 
maintenance of increased levels of effector cells in the inflamed intestine and 
consequently preservation of the inflammation and subsequent disease evolution to 
chronic [16]. Thus, pathogenesis of inflammatory bowel disease is not completely 
understood but, it is well accepted that abnormal mucosal immune response, microbial 
factors and epithelial cell abnormalities can facilitate this response [17]. 
 
The adaptive immune response crucial in IBD are fundamentally driven by T cells, Th0 
cells become activated and differentiate into Th1 or Th2 or Th17 cells. Th1 cells are 
essential in the elimination of intracellular pathogens, Th2 cells are protective against 
parasites and mediate allergic reactions and Th17 can contribute to the clearance of 
extracellular bacteria [54]. 
 
Pathophysiological CD and UC are similar, however the cellular responses observed in 
CD and UC are different, while CD is a dominantly T helper Th1 and Th17 mediated 
process, UC seems to be a Th2 disorder [16].  
 
Particularly in patients with CD it is observed a mediated cellular response dominantly 
Th1 and Th17. More specifically, Th1 activated T cells have the ability to produce 
interferon IFN-γ which in turn will activate dendritic cells and macrophages. Activated 
dendritic cells and macrophages produce cytokines such as interleukin (IL)-1β, IL-6, IL-
12, IL-18, IL-23 and tumour necrosis factor TNF-α. Th17 polarized cells secrete IL-17 
and IL-22 [55-57]. TNF-α and IL-6 are the main factor in the pathogenesis of CD, since 
it induces the expression of adhesion molecules in the vascular endothelium and 
invasion of inflammatory cells into the mucosal layer subsequently occurs [56]. Thus, it 
is very important controlling TNF-α and IL-6 biological action in order to ensure the 
regulation of this process in to control the disease [58-60]. 
 
On the other hand, it is observed in the mucosa of patients with UC a mediated 
response by IL-5 and IL-3 origin an atypical Th2 polarized T cell and natural killer T 
cells response [57,61]. Polarized T cell responses, initiate an inflammatory cascade 
that involves endothelial activation, chemokine production and white blood cell 
recruitment [55]. Triggering and perpetuation of the inflammatory response is related to 
deficiencies in the innate immune response caused by failures in controlling the anti-
inflammatory response through IL-10, transforming growth factor b, macrophages and 
B cells and stromal cells and defective type I IFN production [55]. 
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Figure 3. Cytokines in the pathogenesis of IBD [adapted from Neurath, 2014] 
Legend: GATA3 – Transcription factor ; FOXP3 - Forkhead Box P3 Protein; IEC – Intestinal Epithelial Cells; IFN-γ - 
interferon-γ ; IL - interleukin; NK cell – Natural killer cells; ROR-related orphan receptor gamma; Th - T helper; TGF - 
transforming growth factor; TLR - Toll-like receptor; TNF - tumor necrosis factor; Treg - Regulatory T cells. 
 
 
2. Diagnostic of Inflammatory Bowel Disease 
 
The diagnostic of CD and UC are based on combined results obtained from different 
diagnostic exams available to identify colitis, along with clinical characteristics, family 
history of IBD and phenotypic features [31,32,41]. 
 
The major symptoms generally, depend on the intestinal affected segment and usually 
include diarrhea often with blood, colic abdominal pain and fecal urgency. Beyond 
these, other unspecific symptoms may occur like fever, loss of appetite and weight, 
fatigue and primary amenorrhea [15]. As well as complications like intestinal 
obstruction, perforation of the intestine, abscesses in the abdomen, fistulas, anal 
fissures and in severe cases cancer of the colon in CD and rectal bleeding, fulminant 
colitis and cancer of the colon in UC [31,32,41]. 
Laboratorial tests are enable to analyze biochemical markers to evaluate and 
determine the severity of colitis, like complete blood count, sedimentation rate, c-
reactive protein, ferritin, serum albumin, to evaluate anemia and infection and alkaline 
phosphatase (ALP) determined as a marker of intestinal homeostasis once suggest 
damage and intestinal lesion. Urea, creatinine and alanine aminotransferase (ALT) are 
biochemical markers non related directly with intestine but with external organs, 
representative of external and consequent manifestations of the inflammation represent 
extraintestinal manifestations and secondary effects involved with almost every organ 
system and some of the most frequently involved organs like the liver and kidney 
[31,32]. The fecal occult blood test does the determination of fecal hemoglobin and 
permits the diagnosis and evaluation of various colorectal diseases, once it determines 
the intensity of the hemorrhagic focus in the damage colonic tissue [Hirata et al., 2007]. 
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Stool culture is important to mislead infections caused by microorganisms and parasitic 
infestation, associated with cross-infection. More specifically, is used Anti-
Saccharomyces cerevisiae antibodies and Perinuclear Anti-Neutrophil Cytoplasmic 
Antibodies which allow diagnostic precision in complex cases and distinguish CD from 
UC [62].  
 
Besides these, abdominal X-ray, colonoscopy, endoscopy and biopsy even as 
alternative medical imaging techniques associated with clinical pattern and laboratorial 
tests can confirm and diagnose the presence of colitis as well as determine the extent 
of disease [63,64]. 
 
 
3. Pharmacological treatment of Inflammatory Bowel Disease 
 
The current therapy of IBD encompasses pharmacological, nutritional and surgical 
treatment and aims to control the activity of the disease as well as the prevention of 
relapses, reduction of inflammation, resolution of complications, relief of clinical 
manifestations and induction of remission and its maintenance. The clinical 
recommendations for treatment use the signs and symptoms as markers of the activity 
and severity of the pathology. The severity is not directly related to the extent of 
intestinal involvement, but is determined by medical history, physical examination, and 
endoscopic and radiological studies and should be take into account as they determine 
the dose, dosage and formulation of the drug to be effective [34,65]. 
 
The classic clinical approach to treating IBD is called a step-up. In this approach, the 
treatment strategy begins with the use of less effective drugs but with better safety 
profile. If these drugs do not are effective in inducing the remission of the disease, it is 
recommended to use drugs with high efficacy but with possible more marked toxic 
effects. In contrast to this classic "step up" approach, proposal of a top-down approach. 
This approach advocates the use of biologic and immunosuppressive drugs as first-line 
therapy in patients in whom more complicated course of the disease, in order to avoid 
unnecessary use of corticosteroids, taking into account the spectrum of side effects 
and the high percentage of patients who are dependent or refractory to treatment with 
this class of drugs (Figure 4)  [66]. 
 
 At this point there is no knowledge of a cure, so the treatment of IBD focuses on the 
use of drugs that decrease the inflammatory process and induce remission of the 
disease. The majority of therapeutics have anti-inflammatory activity that allows the 
inhibition of the initial events of inflammation with the migration of inflammatory 
mediators, vasodilation, vascular permeability and leukocyte infiltration [4,5]. Actually, 
therapeutics to the treatment of IBD include a large number of drugs, like 
aminosalicylates, glucocorticoids, immunosuppressants, immunomodulators and 
biologic therapy, which have little selectivity for IBD [4,5]. 
 
In the last decade, the treatment of IBD has evolved considerably, with the appearance 
of several drugs directed to block specific inflammatory chain components. The search 
for these therapeutics that act on specific cytokines and are able to blocking the 
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remaining inflammatory chain, allow avoiding situations of unnecessary generalized 
immunosuppression and seems to be a secure bet on the future. Besides that, despite 
the wide range of therapeutic options mentioned above, only a part of patients achieve 
sustained remission with these drugs and are subject to significant long-term side 
effects. Allied to this it is believed in short future that the treatment of IBD pass through 
a combination of several cytokines capable of cover in several intracellular signaling 
pathways [67]. 
Nowadays recent advances in the pathogenesis of IBD have helped in the 
development of new strategies to reach new therapeutic concepts to IBD and 
consequently future therapies. In the future, the search for new strategies for the 
treatment of IBD should focus on finding specific pathways to treat the disease, 
contrary to what has been developed so far, which will increase the amount and quality 
of therapies practiced to date for IBD, progressively evolve to become broader in 
general options but though more targeted and individualized in patients [68]. 
  
In sum, the treatment of IBD can become complex, especially with the emergence of 
new therapeutic strategies, so it is essential to monitor these patients to ensure the 
efficacy and safety of treatment and an optimization of the adherence to therapy [69]. 
 
 
 
Figure 4. Therapeutic pyramid for the management of IBD  
[adapted of Aloi et al., 2014]. 
Legend: AZA – Azathioprine; 6-MP – 6-Mercaptopurine; MTX – Methotrexate; 5-ASA – 5-Aminosalicylic acid. 
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3.1 Aminosalicylates 
 
Sulfasalazine and related drugs, such as mesalamine, olsalazine and balsalazide, are 
the main ones used types of aminosalicylates. These medicines can suppress the 
symptoms when they appear and reduce the inflammation, especially in the large 
intestine [5].  
 
They are derivatives of 5-amino-salicylic acid (5-ASA), used as first-line therapy UC 
and mild to moderate CD. These drugs have therapeutic effects at the intestinal lumen, 
with various oral formulations, enemas and suppositories, developed to allow better 
distribution of the drug [70,71].    
 
Sulfasalazine consists of two components at the same molecule, sulfapyridine do not 
have substantial therapeutic effect and it believed to contribute to undesirable adverse 
effects and mesalamine (5- aminosalicylic acid – 5-ASA) by its time is the active 
therapeutic key. At the colon the two molecules combined by an azo bond are cleaved 
by bacterial azoreductase freeing 5-ASA and sulfapyridine [5]. 
 
Several methods of action have been implicated for these drugs, including inhibition of 
production of IL-1 and TNF-alpha, production of free radicals and oxidants, as well as 
inhibition of lipoxygenase pathway and nuclear factor kappa B however the exact 
mechanism of action remains unknown [73]. 
 
The vast majority of the side effects of sulfasalazine are related to the sulfapyridine 
molecule. The absence of this molecule in formulations of mesalazine, olsalazine and 
balsalazine may explain the lower incidence of adverse effects of these new drugs [70]. 
 
Mesalazine, olsalazine and balsalazine are considered to be prodrugs, with the same 
nitrogenous binding as sulfasalazine, however the sulfapyridine is replaced by another 
5-ASA (olsalazine) or an inert compound (balsalazine). These compounds act in the 
same locations as the sulfasalazine, being effective in inducing maintenance of IBD 
remission [5]. 
 
3.2 Corticosteroids 
 
Corticosteroids are effective in inducing remission in patients with active CD or UC, this 
class of drugs will suppress inflammation in its early stages, as well as late 
manifestations for moderate to severe relapses of IBD and in patients with no response 
5-ASA oral formulations. However, are not suitable as maintenance therapy because of 
the severe side effects and associated with long-term use [1,73].  
 
Corticosteroids influence the immune response of lymphocytes decrease the 
production of inflammatory cytokines and others inflammatory mediators as nuclear 
factor ƙB [74]. They act through inhibition of several inflammatory pathways like 
suppressing IL transcription, induction of inhibitory κB (IκB) that stabilises the NF-κB 
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complex, suppression of arachidonic acid metabolism and stimulation of apoptosis of 
lymphocytes within the lamina propria of the bowel [1]. 
 
Corticosteroids can be administered orally, as enemas, or systematically in conjunction 
with or without other medications. The most commonly used are prednisolone, 
methylprednisolone, and budesonide [73]. 
 
Corticosteroids, such as prednisolone, which is given orally, can dramatically reduce 
fever and diarrhea, relieve abdominal pain and tenderness, and improve appetite and 
sense of well-being and are the preferred steroid administered in emergency situations. 
However, prolonged use of corticosteroids causes side effects. Generally, high doses 
are taken initially to relieve inflammation and intense symptoms. The dose is then 
reduced, and the medicament is discontinued as soon as possible [73].  
 
Hydrocortisone is a steroid specifically used in patients with short areas of distal 
proctitis and fluid retention difficulty. Budesonide, another corticosteroid, is a synthetic 
corticosteroid recommended as one of the first line for the treatment designed to 
release in the terminal ileum. Budesonide has fewer side effects than prednisolone, 
although it is not as quickly effective and generally does not prevent relapses after six 
months. Can be given orally or as an enema, because of its rapid hepatic metabolism 
and this drug is associated with a lower rate of side effects associated with 
corticosteroids [74]. 
 
3.3 Immunomodulators 
 
 
Immunomodulators or immunosuppressant drugs are immunological modifiers used as 
maintenance therapy in patients with IBD after induction therapy with corticosteroids or 
surgery, patients with severe IBD, dependent or resistant to the action of 
corticosteroids and as treatment of first line of fistulas. These drugs are also 
recommended in patients with severe ulcerative colitis requiring treatment with 
corticosteroids or patients who need a new treatment of corticosteroids within a year. 
Although have side effects immunosuppressant drugs are safer than long term 
corticosteroid therapy and benefit from treatment seem to justify the risk. However, 
more studies to define the optimal duration of treatment, in order to maximize the 
duration of clinical remission, with a minimal risk of potentially lethal complications must 
be done [5].Thiopurines, azathioprine and mercaptopurine, methotrexate and 
cyclosporin are the most commonly immunomodulators drugs used [1]. 
 
Azathioprine and mercaptopurine are medicines that decrease the actions of the 
immune system. They are effective for patients with Crohn's disease who do not 
respond to other medications and are particularly useful for maintaining long periods of 
remission. They significantly improve the general clinical condition, decrease the need 
for corticosteroids, and often cure fistulas. However, these medications may not bring 
benefits before one to three months and may have potentially serious side effects [1]. 
Both, azathioprine and mercaptopurine pro-drugs are thiopurine analogs that function 
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through their active metabolite, the 6-thioguanine nucleotide (6-TGN), which leads to 
inhibition of ribonucleotide synthesis as well as T-cell apoptosis [37]. 
 
Methotrexate is an effective therapy in the induction and maintenance of remission in 
patients with IBD. Recent data demonstrate that, the methotrexate shows a 
considerable response rate in patients with CD or UC, intolerant or unresponsive to 
treatment with azathioprine or mercaptopurine, since some patients cannot tolerate and 
others do not respond to treatment. Treatment with methotrexate is also reserved for 
patients cortico-resistant or dependent. 
This drug inhibits dihydrofolate reductase, blocking DNA synthesis and causing death 
cellular, being important in the treatment of autoimmune diseases. However, the 
benefits of this drug in IBD are a result of anti-inflammatory effects [1]. 
 
Ciclosporin is given in high doses injection, is used to treat IBD since 80s, as it is a 
medicine initially used in organ transplantation. Cyclosporine is a potent 
immunosuppressant drug since is an inhibitor of calcineurin, that prevents clonal 
expansion of T cell subsets. It acts to prevent clonal expansion of T cell subsets. At this 
time, cyclosporine is effective in severe UC that has failed to respond adequately to 
glucocorticoid therapy. This medication may help cure fistulas caused by Crohn's 
disease, but it cannot be used safely for a long time because of side effects such as 
kidney problems, infections, and seizures. Cyclosporine is effective in specific clinical 
settings in IBD, but the high frequency of significant adverse effects limits its use as a 
first-line medication [5].  
 
3.4 Biological Therapies 
 
Biological agents are drugs that act on specific cytokines, blocking the remaining 
inflammatory chain modeling the inflammatory response. In this way, the development 
of these biological agents will allow immune directed blockade problem, avoiding 
situations of unnecessary generalized immunosuppression [1]. In CD the immune 
responses are a characteristic Th1 cells response mediated by TNF-α, and although 
various cytokines are produced in the gut when inflamed, TNF- α is a major mediator of 
the inflammatory process. The administration of humanized monoclonal antibodies is 
an entirely new and potentially highly successful concept for treating IBD [5]. Currently 
at European level the European Medicines Agency (EMA) have several approved 
biological drugs like infliximab, adalimumab and golimumab to UC, anti TNF-α drugs, 
vedolizumab an anti-α4β7 integrin drug to CD and UC, and ustekinumab an anti IL-12 
and IL-23 drug to treat CD. 
 
Infliximab is a modulator of the immune system actions which is derived from 
monoclonal antibodies against tumor necrosis factor (FNT inhibitor) that binds into the 
form of a chimeric immunoglobulin and neutralizes TNF-α [73]. Infliximab is 
administered intravenously and may be used to treat moderate to severe Crohn's 
disease, which does not respond to other medicines, as well as to treat people with 
fistulas and maintain response when it is difficult to control the disease. Side effects 
that may occur with infliximab include worsening of an existing uncontrolled bacterial 
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infection, reactivation of tuberculosis or hepatitis B, and an increased risk of some 
cancers [1,5]. 
Adalimumab is a drug related to infliximab that also aims to regulate the immune 
system, is an anti-TNF agent that blocks TNF- α so as to counteract the inflammation 
[73]. Adalimumab is a fully humanized anti-TNF antibody, administered through a 
series of subcutaneous injections and therefore does not elicit possible reactions to the 
infusion of an intravenous drug, such as infliximab. Adalimumab is particularly useful 
for people who do not tolerate infliximab or who do not respond to it, since it is effective 
inducing and maintain remission in patients with CD that failure immunosuppression 
with other therapies [1,5]. 
 
3.5 Antibiotics 
 
Antibiotics are useful as adjuvant therapy in severe Crohn's disease, but have limited 
use in ulcerative colitis. Antibiotics are often prescribed that are effective against many 
types of bacteria, particularly the use of antibiotics in IBD is based on the possible 
involvement of bacterial flora in the pathogenesis of the disease. The enteric flora is 
altered, and bacteria can be found in the inflamed mucosa, suggesting a possible loss 
of tolerance in patients with IBD. In this way, antibiotics are used in the sense of 
manipulating the intestinal flora, consequently, in the treatment of fistulas, abdominal 
abscesses, bacterial overgrowth and perianal disease [75]. 
 
Systemic side effects can limit prolonged antibiotic use. Although these symptoms 
generally resolve with dose reduction or cessation [37]. The most commonly used 
antibiotics are metronidazole, ciprofloxacin and rifaximin. [37,73,75,76].   
 
The antibiotic metronidazole is the most frequent choice for the treatment of perianal 
abscesses and fistulas. Metronidazole may also help relieve the noninfectious 
symptoms of CD, such as diarrhea and abdominal pain. However, when given in the 
long term, metronidazole can damage nerves, his side effect usually subsides when 
the drug is discontinued, but recurrences of CD are common after discontinuation of 
metronidazole [1,76]. Metronidazole has been in the last decades compared to several 
therapies as the first line in CD and demonstrated equal efficacy in the treatment with 
sulfasalazine. In addition, it was effective in the treatment of patients whose treatment 
with sulfasalazine was not effective. The application of metronidazole in treatment of 
perianal disease in CD has demonstrated statistically significant effects in reducing 
fistula drainage and associated pain [77]. 
 
Ciprofloxacin is used, such as metronidazole, in the treatment of perianal disease, 
showing no significant effect on the remission rates, according to results of a pilot study 
by Thia et al. [77]. Nevertheless, evidence suggests a greater benefit than 
metronidazole in perianal CD and pouchitis [Mowat et al., 2011]. On the other hand, 
ciprofloxacin can lead to Clostridium difficile infection, inducing IBD relapse [76]. 
 
Rifaximin, a nonabsorbent antibiotic, is also used in the treatment of active Crohn's 
disease. Rifaximin proved to be significant in inducing clinical remission with minimal 
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side effects [37,73], however long-term treatment with high doses of rifaximin has been 
associated with urticarial skin side effects [76]. 
 
 
 
4. Prognosis of Inflammatory Bowel Disease 
 
IBD is a heterogeneous condition with a highly variable clinical course, is rarely cured 
and is characterized by intermittent episodes of exacerbations and remissions, with 
some patients following a mild to moderate course while others experience early and 
aggressive disease progression with severe illness and frequent periods of debilitating 
pain. Complicated IBD can evolve to the presence of extra-intestinal manifestations 
and the development of colon cancer consequently with need for colon surgery, 
colectomy. However, with cautious clinical and surgical therapy and with maintenance 
therapy, many patients evolve well and successfully adapt remaining in remission for 
long periods of time [43].  
Several clinical factors associated with complicated IBD can alter the innate pathway of 
disease. In Crohn's disease, young age at diagnosis, small bowel disease, upper 
gastrointestinal extent, stricturing or penetrating behavior, perianal disease, severe 
endoscopic lesions like deep ulcerations and smoking, affect the disease resolution.  
And in Ulcerative Colitis young age at diagnosis, male gender, extensive colitis, severe 
disease activity at diagnosis, high histological inflammation score, the presence of 
primary sclerosing cholangitis, steroid use and steroid resistance, are factors that must 
be taken into account with clinical course of the disease [43]. That way therapeutic 
strategies in IBD result from a delicate and difficult balance between benefits and risks 
of more gentle and aggressive therapies, taking into account the individuality of each 
patient and the surrounding pathophysiological situation that characterizes [1]. 
Disease related mortality is very low, as there is no significant risk associated with 
people with IBD compared to the general population [78].  However gastrointestinal 
cancer, including cancer of the colon and small intestine, is the leading cause of 
mortality associated with Crohn's disease. Patients with IBD depending on the extent 
and duration of the disease have increased risk of develop colorectal cancer. In 
patients with UC the risk of developing colon cancer is much higher when pancolitis or 
left-sided UC is observed contrary when UC is limited to the rectum or rectosigmoid 
this risk does not increase, corroborating the argument that depends on the extent and 
duration of the disease the risk of developing cancer as well as the treatment used in 
the life time of the disease [33]. 
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Chapter 2 - Animal Models of Inflammatory Bowel 
Disease 
1. Animal models of Inflammatory Bowel Disease 
 
Experimental models of inflammatory bowel disease supply considerable information 
on the pathogenesis of this illness, represent an important tool in testing new strategies 
of treatment and playing a pivotal role in the development of novel therapeutic drugs 
once they are capable of characterizing physiologic interactions when our 
understanding of such processes is insufficient to permit replacement of in vitro 
systems [79]. Due to the complexity of the pathophysiology of IBD, the experimental 
animal models used to study these diseases do not accurately represent their 
characteristics, however one IBD patient does not entirely resemble another, hereupon, 
the diversity of responses we observe in animal models is no different than what we 
observe in humans making these animal models useful and valid tools that allow the 
investigation of factors related to pathology and also new strategy therapies [80]. 
Currently used therapy aim to induce and maintain the patient in remission and 
ameliorate the disease´s secondary effects, rather than modifying or reversing the 
underlying pathogenic mechanism, this treatment difficulties lead to the need for further 
preclinical studies with the aim of testing new pharmacological approaches, hence the 
need and pertinence of validating animal models of disease that mimic faithfully the 
disease in human (Table 6) [4,5]. 
There are several types of animal models of IBD, however, experimental models used 
actually are classified in four groups, based on how the disease is formed. Current 
exist spontaneous colitis animal models, as they develop the disease naturally in their 
environment, however, is not a model regularly used due to randomness of disease 
development and difficulties in find these animals, as well as breeding animals to 
develop IBD with this model. The induced colitis by specific immunological or chemical 
agents models normally induce physically an immune response and epithelial damage 
according to induced agent used. A third group, the genetically modified animal models 
by gene knockout, knockin or transgenic methods allow uncover the genetic factor and 
subsequently the candidate gene underlying the disease but are not able to preclinical 
efficacy testing once this model uses a genetic engineered population were only one 
gene is modified in an restricted controlled environment, impossible resemble IBD in 
humans. The last model includes adoptative transfer models, this immunological model 
induces experimental inflammation through transferring specific T cells into an immune 
compromised individual, however due to the extremely complex protocol many factors 
can lead to bias in results, making it a difficult model to mimic IBD [7].  
Ideally, a disease model should closely parallel the human disease in clinical 
manifestations, pathophysiology, and response to existing therapeutic elements. 
However so many animal models are now available and various features like species, 
strains, subtrains, the microenvironment in which animals live and the mediators 
involved in each of these models must be taking into consideration making it difficult to 
the researcher to choose the most appropriate model to use for preclinical testing 
[81,82]. 
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Table 6. Advantages and limitations of using animal models  
[adapted from Vandamme, 2015] 
Advantages Limitations 
Availability of different models; Difference between species; 
Direct information; Variations induced by techniques; 
Possibility to create new models; Differences in genetic regulation; 
Greater analytical potential; Anatomical differences; 
Controlled modification of variables. Various pathophysiological mechanisms; 
 Different responses to drugs. 
 
In this view, one of the most commonly used and studied in greatest detail animal 
model is colitis induced by administration of chemical substances, which are toxic to 
colonic cells, generate intense inflammatory response, recruitment of inflammatory 
cells, representing some of the characteristics observed in human disease. Chemically 
induced colitis is a simple model to be directed, whose disease onset, duration and 
severity can be manipulated [7]. These models require the co-administration of a 
substance that temporally disrupts the mucosal integrity and allow the colitogenic 
components to access the mucosal immune system (Table 7) [6]. There is interest in 
the use and study of more than one animal model since differences between models 
may reflect the different subgroups of patients with IBD, given this, the most commonly 
used are TNBS induced colitis model which promotes a Th1 response, resembling CD 
and DSS induced colitis model that promotes a Th2 response, resembling UC. In 
practice, this pattern of T-cell differentiation is associated with distinct functional 
activities: Th1 T cells are the key players in delayed type hypersensitivity reactions, 
whereas Th2 T cells are potent inducers of antibody mediated immunologic reactions 
[6,83]. Dextran sulphate sodium (DSS) induced colitis and TNBS induced colitis models 
are the most widely used to induce IBD since they symptomatically, morphologically 
and histopathologically resemble human IBD and allow the development and test of 
novel therapeutic strategies [6,84,85]. 
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Table 7. Animal chemically induced models of IBD [adapted from Murthy, 2006] 
 
Model Species Method of induction Time course 
Disease 
location 
Type of 
colitis 
TNBS Rats, mice and rabbits 
TNBS 
enema 
(20-30mg in 
30-50% 
EtOH) 
3 days – 8 
weeks 
Small 
intestine or 
colon 
Acute and 
chronic 
DSS 
Hamsters, 
mice and 
rats 
2 - 10% DSS 
feeding 
5 days – 15 
weeks/ Colon 
Acute and 
chronic 
Acetic acid Rats 
1 – 10% 
acetic acid 
enema 
1 day – 3 
weeks Colon Acute 
Carrageenan 
Rats, guinea, 
pigs and 
rabbits 
Variable oral 
dosing 1 – 4 weeks 
Cecum and 
colon 
Acute and 
chronic 
Indomethacin Rats Oral or SC once or twice < 1 - 8 days 
Small 
intestine Acute 
Oxazalone Mice and rats Intracolonic Rapid Colon Acute 
 
Legend: DSS - Dextran Sulfate Sodium, TNBS - Trinitrobenzene Sulfonic Acid 
 
 
1.1 Dextran sulfate sodium-induced Colitis 
 
DSS is actually one of the most regularly used colitis inducer to trigger bowel 
inflammation in animal models, largely due to is ease of use and brief obtained results 
and that morphologically and symptomatically resembles UC in humans [7,86]. 
To cause inflammation in rats or mice DSS protocol uses DSS added to drinking water, 
then acute or chronic colitis model experiments can be conducted only by altering the 
concentrations of the administered substance as well as the number of cycles of supply 
of the chemical agent. The severity of colitis caused by DSS depends on dose, 
duration of administration and animal strain [86-88], as well as, the manufacturer and 
molecular weight of DSS, gender and animals raising environment like germ-free or 
specific pathogen free environments [89,90]. 
DSS seems to induce colonic damage through a chemically process where the gut 
mucosa barrier integrity is injured, allowing luminal antigens access to the lamina 
propria and the pro-inflammatory cells [90]. Furthermore, the bacteria present in gut are 
able to dissociate sulfate from DSS, leaving free in the bowel a sulfate molecule which 
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helps as substrate to produce hydrogen sulfide. Hydrogen sulfide induce a toxic effect 
on epithelium since it might expressively affect cellular metabolism. On the other hand, 
DSS probable promotes variations in luminal bacterial ecosystem and the activation of 
monocytes, macrophages and mast cells [7,91].  DSS increases the production of all 
pro-inflammatory cytokines in colon, particularly TNF-α levels and promotes chronic 
pathological changes which involve changes in the morphology of crypts with changes 
in Th1/Th2 cytokine profile and central memory T cells. Besides that, have been shown 
that DSS induced significant macrophage infiltration into the epithelium of the colon 
[92].  
The DSS colitis model is very popular in IBD research due to its rapidity, simplicity, 
reproducibility and controllability. The addition of DSS to drinking water, modifying the 
concentration of DSS and the frequency of administration permit obtain a very 
reproducible acute or chronic and relapsing model of intestinal colonic inflammation, as 
well as a useful model for a better understanding of the innate immune mechanisms of 
UC [7]. DSS is usually administered in a dose range of 2-10% for 5-10 days to induce 
acute inflammation following a single continuous exposure. By prolonging DSS 
administration, acute colitis may be extrapolated to chronic colitis by repeated 
exposure administered in three to five cycles interrupted with recovery periods 
[6,84,85]. However, DSS model is very expensive among other disadvantages like 
variations in disease severity could occur due to small molecular weight DSS impurities 
in the DSS preparation. Besides, the disease is characterized by progressive crypt 
dropout, suggesting a direct effect of DSS on the epithelial cells as opposed to lamina 
propria cells as suggested in human IBD [91]. 
 
1.2 Trinitrobenzene sulfonic acid-induced Colitis 
 
TNBS model is a commonly used model of IBD to study the pathogenesis of colitis as 
well as in preclinical studies, in 1989 was described by the first time by Morris and 
since then have become a popular and important tool mimic the pattern of inflammation 
in human IBD. TNBS is capable of reproduce CD in humans once promotes a Th1 
immune response with characteristic chronic transmural colitis and consequently 
severe diarrhea, weight loss and rectal prolapse. TNBS model is an easy induced, 
rapid, reliable, robust and a highly reproducible animal model of intestinal inflammation. 
The induction of the disease occurs quickly and appears 4 to 7 days after intrarectal 
administration of the TNBS hapten reagent, gradually progressing into chronic pattern 
during at most approximately about 8 weeks [83,93,94].  
 
Inflammation caused by TNBS histologically is characterized by focal ulcers, crypt 
distortion, depletion of goblet cells, presence of granulomas, thickening of the intestinal 
wall, edema, infiltration of inflammatory cells and necrosis [7,8]. 
 
Protocols of the chronic TNBS-induced colitis model are not standardized concerning 
the dose of TNBS, the depth of TNBS administration, the animal strain, and the time 
point for model evaluation [7]. 
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The experimental model with TNBS consists in the induction of intestinal inflammation 
by a chemical process in which colitis is induced by rectal instillation of 20-80mg of 
2,4,6-trinitrobenzenesulfonic acid in an ethanol solution of 30-50% , ethanol will act to 
break the membrane, whereas TNBS acid would act with a hapten which associated 
with substances with high molecular weight such as tissue proteins, would be able to 
trigger an immune response. This model is based on increased permeability of the 
membrane that occurs in IBD, which facilitates the entry of a luminal antigen that is not 
adequately eliminated by the immune system, the haptenization [82,95]. Ethanol, by his 
side, permeabilizes the epithelial layer that separates the luminal contents of the colon 
from the cells of the mucosal immune system, allowing the penetration of TNBS in the 
bowel wall (Figure 7) [82,96]. 
 
TNBS induces acute and chronic form of colitis dependent of dose and frequency of 
administration, reacting with some amino acid groups on intestinal mucosa and 
bacterial proteins of the colon and rendering them immunogenic. TNBS haptenates 
autologous colonic proteins with a trinitrophenyl moiety and induces an IL-12 mediated 
Th1 T cell transmural colitis, which resembles human IBD, both on a histologic and 
immunologic level. TNBS associated with ethanol promotes the development of severe, 
transmural, granulomatous inflammation in the distal colon [82,95]. 
 
 
 
Figure 5. Mechanism of colitis induction and tolerance in the TNBS-induced colitis 
model [adapted of Strober et al., 1998] 
Legend: TNBS - Trinitrobenzene sulfonic acid; APC – Antigen presenting cells; MAC - Membrane attack 
complex; TNF-α - Tumour necrosis factor α. 
 
With this model induction occurs increase enzymatic activity of myeloperoxidase and 
alkaline phosphatase and increased expression of pro-inflammatory cytokines such as 
TNF-α and interleukins, as well as changes in the antioxidant systems of the intestinal 
mucosa. The presence and recognition of TNBS promotes IL-12 secretion and induces 
the response of Th1 cells, which produce INF-γ, this acts on macrophages inducing the 
production of pro-inflammatory cytokines such as TNF- α, IL-1 and IL- 6, triggering the 
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inflammatory process. In addition to these other inflammatory mediators are involved 
as prostagrandins E2, thromboxane B2, leukotriene B4 and C4 and other interleukins 
[7,8,97]. 
 
 The main advantages of this model include a simple and low-cost protocol and 
reproducible colonic damage, short experiment duration, enduring damage 
accompanied by inflammatory cell infiltration and ulcers. On the other hand, the TNBS 
colitis model has some disadvantages, such as the absence of spontaneous relapse 
that is the hallmark of IBD and model reproducibility depends on the TNBS dose [97]. 
Thus, TNBS chemically induced model is a useful and important experimental model to 
mimic IBD, as it allows the study of the initial events of inflammation and the 
subsequent analysis of the intestinal mucosal immune response triggered by a specific 
antigen and consequent pathogenesis and new metabolic pathways of the disease, 
making it possible to evaluate various mediators involved in the inflammatory response 
and new compounds to treat UC or CD  to achieve new pharmacological approaches to 
the treatment of the disease [7]. 
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Chapter 3 – Materials and Methods 
 
Chemicals/Materials 
 
2,4,6-Trinitrobenzene sulfonic acid (TNBS 5%) and sodium chloride (NaCL) were 
purchased from Sigma Chemical Co. Ketamine (Imalgene® 1000) was purchased from 
Merial. Xilazine (Rompun® 2%) was purchased from Bayer. ADVIA® kit was purchased 
from Siemens Healthcare Diagnostics. ELISA assay kits for TNF-α and IL-10 
measurements were obtained from Hycult Biotechnology. 
 
Animals 
 
The mice female CD-1 were obtained from Charles River – Barcelona, Spain, with 
weight of 25-40g and 6-10 weeks of age. The animals were kept in the Molecular 
Medicine Institute in Faculty of Medicine of the University of Lisbon biotereum under 
controlled conditions of access to water and food (ad libitum), at a temperature 
between 18-23ºC and humidity of 40-60% in standard polypropylene cages. Animal 
care was in strict accordance with internationally accepted principles for laboratory 
animal use and care, Directive 2010/63/EU. The experiment was approved by the 
institutional animal ethics committee of Faculty of Pharmacy, University of Lisbon. 
 
Induction of Experimental Colitis 
 
In this study was used a chronic chemical model of colitis induction with multiple 
administrations.  The animals were submitted to a briefly fasting period of 24h. In the 
induction day (day 0) the mice were anesthetized with 40µl ketamine 100mg / kg + 
xylazine 10mg / kg by intraperitoneal injection (IP). Thereafter, the rectal administration 
of 100µl TNBS solution was performed by introducing a catheter up to 4cm into the 
mice colon. To prevent colonic reflux the mice were post-maintained in Trendelenburg 
position [7]. The procedure was repeated weekly, at day 7 of each week, during a 
period of 6 weeks in order to obtain a chronic model of colitis induced by TNBS. Every 
week, on days 7, 14, 21, 28, 35 and 42, depending on the experimental group 
respectively, blood samples of mice were collected by cardiac puncture, under 
anesthesia, immediately before euthanasia. Mice were sacrificed by cervical dislocation 
and necropsied. The abdomen was opened with a middle incision and the colons were 
removed, released from enclosed tissues, washed with phosphate-buffered saline. 
Colon length was also measured as a marker of tissue integrity, determined using a 
measuring scale and analyzed for intestinal damage, taking into account macroscopic, 
histopathological and biochemical parameters of the inflammatory process. 
Macroscopic score evaluation of the colon was based on described by Morris et al 
1989 [8], Criteria for scoring of gross morphologic damage (Table 8), together with the 
evaluation of presence of diarrhea and adhesion in colon. 
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Table 8. Criteria for Scoring of Gross Morphologic Damage 
[adapted from Morris et al. 1989] 
 
Experimental Groups 
 
An experiment was performed on the development of the procedure where mice were 
randomized into 8 groups, accordingly to the main objective of this study, namely the 
development of a TNBS induced chronic colitis model (Table 8). Experimental groups 
were categorized as TNBS 1 group (n=15), TNBS 2 group (n=15), TNBS 3 group 
(n=15), TNBS 4 group (n=15), TNBS 5 group (n=15) and TNBS 6 group (n=15), 
received all 100µl intrarectal 1% TNBS in 50% ethanol weekly, depending on the 
number of administrations; ethanol group (n=15) received 100µl intrarectal 50% 
ethanol (TNBS vehicle) and sham group (n=8) received 100µl intrarectal saline 
solution. All groups were maintained under the same conditions. The animals in the 
control groups were placed in cages separated from the cages of the animals that 
would undergo colitis induction. The ethanol and sham group were used as reference 
to compare with other experimental groups (Table 9). 
 
 
 
 
 
 
 
 
 
Score Gross morphology 
0 No damage. 
1 Localized hyperemia, but no ulcers. 
2 Linear ulcers with no significant inflammation. 
3 Linear ulcer with inflammation at one site. 
4 Two or more sites of ulceration and/or inflammation. 
5 
Two or more major sites of inflammation and ulceration or one major site 
of inflammation and ulceration extending >1 cm along the length of the 
colon. 
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Table 9. Scheme of study design of the experimental groups. 
 
 
 
 
Legend: † - Euthanized on 
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Monitoring of Clinical Signs 
 
During the experimental development the animals were observed daily and monitored 
clinical signs throughout the evaluation of different parameters such as body weight, 
morbidity, stool consistency and anus appearance. 
 
Biochemical Markers 
 
Before the mice be killed, were anesthetized and blood samples collected by cardiac 
puncture. Serum collected from blood samples were separated by centrifugation at 
3600rpm for 15 minutes and analyzed by an automated clinical chemistry analyzer 
(ADVIA 2400). The biochemical markers such as alkaline phosphatase (ALP), urea, 
creatinine and alanine aminotransferase (ALT) were evaluated spectrophotometrically, 
and a quantitative method by immunoturbidimetry (Kroma Systems) was used to 
evaluate fecal hemoglobin, as an index of hemorrhagic focus. Alkaline phosphatase 
(ALP) was determined as a marker of intestinal homeostasis, urea was determined as 
a marker of renal function, creatinine as a marker of renal function and alanine 
aminotransferase (ALT) was determined as a marker of hepatic function.  
 
Measurement of Cytokines 
 
The pro-inflammatory cytokine TNF-α and the anti-inflammatory cytokine IL-10 were 
measured in the colon according to the manufacturer's recommended protocol, and 
expressed as pg/ml. To cytokine dosing, colon samples were weighed and 
homogenized (Ultraturrax T25, 13.500rev/min, twice for 30s) in phosphate buffer and 
centrifuged at 15.000rpm for 15min at 4ºC. The samples of supernatant were kept at -
20o C for further enzymatic assay. The reaction to determine the cytokine levels was 
stopped and the plates were measured in a spectrophotometer at 450nm (ELISA kit 
Quantikine, Hycult Biotechnology). 
 
Hystopatological Analysis 
 
The histopathological analysis of bowel tissues from all mice groups was done by 
independent histopathologists blinded to the treatment groups from Institute of 
Molecular Medicine (IMM). The colon samples of the animals were removed shortly 
after euthanasia and fixed in 10% phosphate-buffered formalin and processed for 
paraffin embedding. After, the tissues were sectioned at 5µm and stained with 
hematoxylin and eosin. Longitudinal sections of distal colon were evaluated based on 
adapted criteria of Corazza and colleagues [9] and Seamons and colleagues [10].  
 
Microscopic Assessment of Colitis Severity 
 
The sections were examined and scored according to the presence of inflammation (0-
4 increasing severity) with some parameters, namely: (1) presence of tissue 
loss/necrosis, (2) severity of mucosal epithelial lesion, (3) inflammation, (4) extent 1 - 
the percentage of intestine affected in any manner and (5) extent 2 - the percentage of 
intestine affected by the most severe lesion. The colitis severity was calculated by 
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summing the individual lesions and the extent scores, promoting a final colitis score 
(max score=20)(Table 10). 
 
Table 10. Scoring system of histopathologic evaluation of TNBS induced colitis. 
Points Tissue Loss Epithelial Lesion Inflammation Extent 
0 None None None None 
1 Mucosa ≤ 50% Mild mucous cell depletion 
Mild - mucosa 
only ≤5% 
2 Mucosa ≥ 50% 
Moderate 
mucous cell 
depletion 
Moderate - 
mural 6-30% 
3 Mural Severe with aberhant crypts Transmural 31-60% 
4 Transmural Severe with cryp loss 
Extension to the 
mesentery ≥61% 
 
 
 
Statistical Analysis 
 
All the results were statistically analyzed with a p-value of less than 0.05 considered 
significant. All results were expressed as mean ± SEM of N observations, where n 
represents the number of animals studied. Data analysis was performed by using 
GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). The results were 
analyzed by one-way ANOVA to determine statistical significance between the 
experimental and control groups followed by Tukey’s post hoc test for multiple 
comparisons or chi-square test depending on the variables under study. 
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Chapter 4 – Results 
 
The induction of the acute disease occurs 4 to 7 days after intrarectal administration of 
the TNBS hapten reagent, gradually progressing into chronic [11,8,12]. Since the 
protocols of the TNBS-induced colitis model are not standardized the experimental 
protocol was performed, with six independent groups of TNBS-induced colitis and 
developed and monitored under the same specific conditions. Mice were sacrificed 7 
days after each instillation, during a period of 6 weeks. Thus, to identify the chronic 
pattern associated with IBD with the induction method used on this study. 
 
Monitoring of Clinical Signs 
 
The mice were observed daily during the complete experimental protocol taking into 
account parameters like morbidity, body weight, stool consistency and anus 
appearance. On week 2 until week 4 the generality of mice presented alterations of 
intestinal motility characterized by soft stools, slight edema of the anus and moderate 
morbidity. Apparently, after week 4, the mice presented adapted to TNBS and an 
apparently recover, revealing less exacerbated clinical signs and consequently less 
morbidity. With reference to ethanol and sham groups, taking into account the same 
clinical signs during, all experimental period, were not identified any alteration, 
according to control groups. Concerning body weight, all TNBS groups demonstrated a 
very similar curve in the register of body weight each week (Figure 8). Until week 4 was 
observed a progressive increase in body weight common to all groups. In turn, on week 
3 a slight decrease in mice body weight of the groups was observed. Ending the TNBS 
6 group, mice had more 13.32 ± 2.7% of its initial weight. The ethanol and sham 
groups presented a considerable increase in body weight. At the end of experimental 
period, the ethanol and sham groups gained 12.74 ± 2.3% and 13.08 ± 2.4% of its 
initial weight, respectively. 
 
 41 
 
 
Figure 6. Change of body weight during the development of TNBS-induced colitis 
The colons were observed macroscopically and scored to gross morphology according 
to the Morris method. The maximal damage in the colon where observed with two 
instillations, at group TNBS 2, the score mean observed was 2.67 ± 0.67 (p<0.0001) 
correspondent with the classification, linear ulcer with inflammation at one site. By 
comparison at week 4 onwards the evaluation score decreased to 0.43 ± 0.20 
(p<0.0001) correspondent with localized hyperemia, but no ulcers. The control groups, 
ethanol and sham present a colon classification of no damage with a score of 0 to both 
groups (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Gross morphology damage score during the development of TNBS-induced 
colitis. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.0001 compared with sham group or between 
groups. 
 
*** 
 *** 
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Survival curves indicate the probability that the product will survive until a certain period 
of time. The survival curve designed by our study group demonstrates along the 
experimental procedure a high-pitched drop in survival at the first two weeks. In the first 
week survival decreased to approximately 62%, and in the second week a new 
decrease occurs to values of 50%. After week 2 onwards the mice survival maintains 
the same values until the end of the experimental protocol indicate stability and 
adaptability of animals to disease (Figure 10). 
 
Figure 8. Effect of TNBS-induced colitis on survival in the IBD. 
 
Biochemical Markers 
 
The colon length was determined at the end of the treatment period, using a measuring 
scale (Figure 11). The influence of TNBS induced colitis in the colon length comparing 
with control groups was observed, however with no statistical significance. The TNBS 
groups did not display significant changes compared to the sham group. More 
specifically, the TNBS 4 group presented around 8.5 ± 0.21 cm of colon and, contrary 
to what was observed in the initial week, TNBS 1 has 9.9 ± 0.55 cm, values that 
remained more or less constant over the course of the experience, TNBS 6, with 8.7 ± 
0.30 cm. On group TNBS 4, the colon length of TNBS group was considerably lower 
than control groups, as ethanol and sham groups, which presented 9.2 ± 0.3 cm and 
9.5 ± 0.5 cm of colon, respectively. 
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Figure 9. Effect of TNBS-induced colitis on colon length in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test. 
 
The fecal hemoglobin was evaluated as an index of hemorrhagic focus in the damage 
colonic tissue (Figure 12). On week 2, the mice with colitis had 2.6 ± 0.3 µmol Hg/g 
feces and, in the week 6 of administration of TNBS, the fecal hemoglobin considerably 
increased to 7.5 ± 0.5 µmol Hg/g feces (p<0.0001). Thus comparing TNBS 4 fecal 
hemoglobin values with TNBS week 6, no statistical significance was observed. By his 
side the comparation between TNBS and sham group demonstrate an augmented level 
of fecal hemoglobin in the end of the experiment (p<0.0001). The control groups 
presented very low concentrations of fecal hemoglobin with 2.1 ± 0.24 µmol Hg/g feces 
on ethanol group and 1.6 ± 0.12 µmol Hg/g feces on sham group.  
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Figure 10. Effect of TNBS-induced colitis on fecal hemoglobin in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.0001 compared with sham group or between 
groups. 
 
The ALP dosing is associated to the presence of intestinal lesion hereupon it was 
evaluated his concentration on blood (Figure 13). At TNBS 2 a decreased value of ALP 
was dosing in serum comparing with sham group, 21.67 ± 2.7IU/L, however with no 
statistical significance. The ALP levels observed were in the majority higher than those 
observed by the control groups, with a maximum level at week 5 of 58.5 ± 2.18 IU/L, 
compared with sham group (p<0.0001). Nevertheless, according to the different 
parameters analyzed the maintenance of the values after week 4, 39.67 ± 2.45 IU/L, 
until the end of the experiment, TNBS 6, 44.38 ± 2.3IU/L, with no statistical 
significance. Ethanol and sham groups presented concentrations of ALP with around 
33.17 ± 1.5 IU/L and 30.5 ± 0.88 IU/L, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Effect of TNBS-induced colitis on serum total ALP concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.0001 compared with sham group. 
           *** 
           *** 
           *** 
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Urea and creatinine are biochemical markers nonrelated directly with intestine allowing 
the assessment of renal damage based on urea and creatinine concentrations (Figure 
14 and 15). Regarding blood urea levels starting to verify a similar dosing result over 
the entire trial period. The TNBS 1 and sham groups presented a urea concentration of 
83.0 ± 1.55 mg/dl and 81.6 ± 0.86 mg/dl, respectively. Comparing TNBS 6 with sham 
group (77.4 ± 1.86 vs 81.6 ± 0.86 mg/dl), urea maintained levels of the same order of 
magnitude, with no statistical significance observed. By his side creatinine had a similar 
values pattern, when compared with the ethanol group, the TNBS group 1 (0.54 ± 0.01 
mg/dl) had a significantly higher creatinine concentration (p<0.01), comparing with 
ethanol group, 0.41 ± 0.03 mg/dl. By his side TNBS 1 comparing with TNBS 3 shows 
decreased values with statistical significance (p<0.01). TNBS 4 with ethanol group 
demonstrate statistical significant values, with high levels on week four (p<0.001). 
TNBS 6 compared with sham group (0.51 ± 0.02 vs 0.43 ± 0.02 mg/dl), reveals no 
statistical significance. The ethanol group presented 77.17 ± 2.20 mg/dl of urea and 
0.41 ± 0.03 mg/dl of creatinine. There are no statistically significant differences in urea 
and creatinine levels comparing to the control groups. 
 
Figure 12. Effect of TNBS-induced colitis on serum urea concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test. 
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Figure 13. Effect of TNBS-induced colitis on serum creatinine concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.01 compared with ethanol group or between groups; 
p<0.001 compared with ethanol group. 
 
ALT concentration in serum was evaluated as a hepatic marker of liver homeostasis 
(Figure 16). TNBS group 1 ALT levels were 28.14 ± 1.96 IU/L comparing with sham 
group (p<0.01). The ALT concentration starts to increase significantly in the TNBS 
week 4 group compared with the sham group (35.0 ± 1.6 vs 19.3 ± 0.54 IU/L, 
p<0.0001). On week 6, the ALT maintained approximately the values 35.75 ± 1.5 IU/L 
compared to TNBS day 4 group, but yet for higher values than sham group (p<0.0001). 
The ALT concentration on ethanol group (24.67 ± 1.69 IU/L) was higher than the sham 
group (19.30 ± 0.54 IU/L) although without statistically significant differences. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Effect of TNBS-induced colitis on serum ALT concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
 
           
* 
           *            
** 
           
*** 
           
*** 
           
* 
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Measurement of Cytokines 
 
The TNBS-induced colitis showed a significant production of pro-inflammatory 
cytokines, as TNF-α comparing to sham and ethanol groups (Figure 17). All TNBS 
groups presented higher levels of pro-inflammatory cytokines than sham group. The 
TNBS 1 group has higher values statistically significant, when compared with group 
TNBS 2, (79.59 ± 5.89 vs 51.5 ± 2.9 pg/mL, p<0.001). The highest level of TNF-α was 
registered at TNBS 3 administration, 87.58 ± 13.13 pg/ml, compared with week 6, 
72.70 ± 3.6 pg/ml, without statistical significance, indicating a maintenance in the 
values along with time. The TNBS 4 was also compared with sham group, since 
statistically significant values were observed demonstrate the augmented pro-
inflammatory cytokines levels in this model (71.34 ± 3.28 vs 39.69 ± 2.4 pg/mL, 
p<0.001). Even, the ethanol and sham groups had very similar concentrations of pro-
inflammatory cytokines, without statistically significant differences. The ethanol group 
presented 39.80 ± 1.5 pg/ml of TNF-α and the sham group presented 39.69 ± 2.4 
pg/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Effect of TNBS-induced colitis on TNF-α concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
 
The TNBS-induced colitis showed a significant production of anti-inflammatory 
cytokines, IL-10, (Figure 18). Contrary to expected increased IL-10 values are 
observed simultaneously with the increase of pro-inflammatory cytokines such as TNF- 
α. Usually the IL-10 decrease when the TNF-α concentrations increase under 
inflammatory conditions. The TNBS 1 group as 53.39 ± 3.17 pg/ml when compared 
with sham group, 33.99 ± 1.7 pg/ml, p<0.01. Comparing TNBS 3 with TNBS 6 an 
increase is observed congruent with the evolution of pro-inflammatory cytokines along 
with the inflammation (44.56 ± 3.73 vs 68.21 ± 1.76 pg/mL, p<0.0001). At week 6 the 
IL-10 values were 68.21 ± 1.76 pg/ml without statistical significance when compared 
with TNBS 4 group, 57.34 ± 3.81 pg/ml, demonstrate a constant level of IL-10 along 
with the experimental study. The control groups, as ethanol and sham groups, had 
similar results with 43.73 ± 3.7 pg/ml and 33.99 ± 1.7 pg/ml of IL-10, respectively.  
         
*** 
         
*** 
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Figure 16. Effect of TNBS-induced colitis on IL-10 concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.0001 compared with sham group or between 
groups, **p<0.001 compared with sham group. 
 
Hystopatological Analysis 
 
The data regarding histopathological analysis performed in the studied colons were not 
obtained during the period of development of this dissertation. 
 
  
         
** 
         *** 
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Chapter 5 – Discussion 
 
IBD is a chronic inflammatory disorder of the epithelium of the intestinal tract caused by 
multiple factors and for which therapeutic options are limited [1,2]. Patients with IBD 
have increased intestinal permeability, barrier disfunction of the epithelium and 
cumulative exposure to antigens leading to activation of the immune system, 
production of pro-inflammatory cytokines and reactive oxygen species resultant in 
intestinal mucosa lesions [4]. 
Experimental models of IBD supply considerable information on the pathogenesis of 
this illness, regardless of they don’t fully reflect the complexity of the human disease 
and has several disadvantages they represent an important tool in testing new 
strategies of treatment, since they mimic the features of the disease [6,7]. TNBS 
model, particularly, is a commonly used model of IBD to study the pathogenesis of 
colitis since its capable of reproduce CD in humans once promotes a Th1 immune 
response with characteristic chronic transmural colitis [6,83,94]. Additionally, TNBS 
model can mimic acute and chronic stages of IBD, through a simple and short 
experiment with reproducible and long-lasting colonic damage accompanied by 
inflammatory cell infiltration and ulcers [98,99]. The experimental model with TNBS 
consists in the induction of intestinal inflammation by a chemical process in which 
colitis is induced by rectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS), the 
haptenating substance, in an ethanol solution, leads to deregulation of the mucosal 
immune system [100,101].  Thus the main aim of this project is to develop a preliminary 
study towards a novel chronic experimental model to study IBD in order to support a 
future new model of chronic induced colitis in rodents using TNBS.  
In this study, it was used a chronic chemical model of colitis induction based on the 
described by Morris et al. [8]. Since the protocols of the TNBS-induced colitis model 
are not standardized [12], the experimental protocol was performed, with six 
independent groups of TNBS-induced colitis and consequently developed and 
monitored under the same specific conditions, however sacrificed on day 7 of each 
week after instillation, during a period of 6 weeks. The mice were evaluated taking into 
account parameters like clinical symptoms such as body weight, stool consistency, 
anus appearance and colon length and biochemical markers such as ALP, urea, 
creatinine, ALT, fecal hemoglobin, TNF-α and IL-10. TNBS-induced chronic colitis 
model was developed with the main objective to providing a chronic pattern of intestinal 
inflammation disease. 
Regarding monitoring of clinical signs, TNBS group presented an alteration of intestinal 
motility characterized by diarrhea or soft stools, edema of the anus and moderate 
morbidity, while ethanol and sham groups remained without any alterations. The 
manifestations became more exacerbated at week 2 after induction and the effect 
maintain with more light signs in the next weeks. The TNBS 1 group presented 
moderate morbidity, the TNBS 2 group revealed high morbidity and the TNBS 4 group 
onwards presented mild morbidity. The sham group remained without any alterations.  
These clinical manifestations in the TNBS groups were expected and compatible with a 
correct chronic induction of CD [97,102].  
The peak of clinical signs was also confirmed by a slight progressive increase in body 
weight in the entire experimental procedure with around 13.32 ± 2.7 % of weight gain, 
consistent with other research groups [97,102,103]. Three weeks after the initial 
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induction day, all TNBS groups presented a decrease in body weight, demonstrating 
that sick mice became weaker, with recovery body weight in the next weeks. Regarding 
control groups, they presented a considerable increase in body weight with a gain of 
12.74 ± 2.3% ethanol group and 13.08 ± 2.4% sham group of its initial weight. In fact, 
they were fasted for 12 hours since the day before of the induction day. After induction, 
they woke up from anesthesia, felt healthy and prepared to eat, unlike the other groups 
with experimental colitis, thus justifying the increase. 
TNBS-induced colitis promotes a reduction in the colon length compared to the sham 
groups [103,104]. In our study TNBS-induced colitis effect colon length on week 2, after 
that, the colon length significantly recovered TNBS effects, but in the following weeks 
the mice maintaining the effects on the colon length, suggesting that a exacerbated 
damage manifested on week 2 occurs, with maintaining effects from week 4 until the 
end of the experiment. In this study, mice without TNBS-induced colitis showed a 
normal colon length with approximately 10 cm, however we verified that TNBS-induced 
chronic colitis promotes a reduction of 1,5 cm in the colon length compared with sham 
group and, however, there was no significant variance between the TNBS groups and 
the sham group, although consistent with the findings from other research groups 
[103,104]. 
Regarding fecal hemoglobin it is expected to have higher values in the TNBS groups 
as opposed to the control group. The fecal hemoglobin was evaluated as an index of 
hemorrhagic focus in the damage colonic tissue and allow the detention of bleeding 
lesions for the diagnosis of several colorectal diseases with active inflammation. 
[105,106].The fecal hemoglobin also confirmed the maintain of TNBS-induced chronic 
colitis effect from 4 week onwards, since we verified a significantly increase of around 4 
µmol Hg/g feces until week 6, evidence the presence of hemorrhagic ulcers. The 
control groups presented residual concentrations of fecal hemoglobin. 
The ALP concentration on blood is a crucial marker regularly measured due to his 
essential role in intestinal homeostasis. [107,108]. ALP is expressed on the surface of 
enterocytes and is responsible for mucosal defense, promoting the interaction between 
the toll-like receptor-4 in the intestinal mucosa and the lipopolysaccharides derived 
from bacterial flora [109]. TNBS groups presented the highest values of serum total 
ALP concentration comparing with the control groups and increased ALP values were 
maintained from the fourth week onwards. The ALP concentrations detected for control 
groups where decreased comparing with the TNBS groups suggesting that the 
increased levels observed in TNBS groups where due to intestinal lesion inducted in 
this study. By his side, the ethanol has the facility to induce an intestinal permeability 
alteration origin colon injury. The ALP blood concentration results from group ethanol 
prove this damage since presented a slight increase of ALP compared with sham 
group. These our results are consistent with other studies, since higher serum ALP 
levels are confirmed in the chronic intestinal inflammation model induced by TNBS 
[110]. 
Cytokines are molecules involved in signal emission between cells during the triggering 
of immune responses. Cytokines are crucial for fighting infections and other immune 
responses. Pro-inflammatory cytokines work by promoting the inflammatory process, 
ensuring that reactions occur, and the initial insult is eliminated. Anti-inflammatory 
cytokines, by his side, act as a brake on this process, preventing an exacerbated 
response and possibly producing undesirable effects of the inflammation itself and the 
healing process [111]. TNF-α is a pro-inflammatory cytokine produced during the innate 
immune response of IBD [112]. TNF-α is associated to the pathogenesis of colitis, 
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since is increased in inflamed colon tissue [113,114]. Our obtained results confirm that 
the used TNBS induced colitis model promotes a significantly increase in the levels of 
TNF-α in the colon. Specifically, these cytokines registered a high level at week 3 and 
maintain these high values exacerbated until week 6 indicating an eventual onset of the 
chronic phase of this inflammatory disease. IL-10 plays a central role in the mucosal 
immune system by inhibiting proinflammatory cytokine synthesis and antigen 
presentation, and at the same time relieves intestinal inflammation [115].The presence 
of anti-inflammatory cytokines, as IL-10 was measured parallelly and the obtained data 
contrarily of what was expected allows concluding that TBNS-induced colitis promotes 
increased production of IL-10, observed after week 3. These results are congruent with 
the hypothesis that the immune system in presence of a chronic inflammatory insult 
tent to dispel the disease, balance values of biochemical markers of inflammation and 
consequently reestablish homeostasis [116,117]. 
Extraintestinal manifestations can involve almost every organ system and some of the 
most frequently involved organs are the liver and kidney [118,119]. Regarding to the 
urea and creatine evaluation, biomarkers of renal damage, the TNBS induced colitis 
doesn’t present considerable alterations comparing with control groups. The ALT 
evaluation related with the hepatic function presented a significantly alteration in TNBS 
induced colitis values comparing with control groups. The high values of ALT were 
detected after week 4, remaining until the end of the experiment. Concerning our 
results TNBS-induced colitis suggests alterations in the liver but no significant 
damages in renal function.  
Regarding the surveillance rate in our study we observed a surveillance decrease in 
the two first week of the procedure of approximately 50%, followed by a conservation in 
the levels obtained until the end of the study. These results are coincident with the 
peak of the disease. On the other side until the end of the experiment mice survival 
maintains indicate stability and adaptability of animals to disease as in the chronic 
pattern associated with this model. 
In our study, a TNBS-induced colitis model was monitored for 6 weeks, since we 
wanted to achieve a chronic pattern of induced colitis and identify the week in which 
the damage become chronic. Manifestations became maximal on day 4 after induction 
and the effect began to decline from that day. Clinical manifestations of chronic colitis 
usually peak within 2 weeks and may be followed by partial recovery or death. These 
were expected and compatible with the correct induction of colitis [120-123]. Indeed, all 
clinical signs, biochemical markers, histopathological analysis and concentrations of 
pro- and anti-inflammatory cytokines, under evaluation, corroborate that the week from 
which a chronic illness pattern is observed is week 4 after the induction. Possibly, 
because some mice died during the early days of the study, no resisting to aggravation 
of the disease in its acute phase, while the remaining mice resisted and progressed to 
chronic phase of the disease, showing the same symptoms but more lightly. These 
preliminary data allow concluding that TNBS-induced chronic colitis should be 
developed in 4 weeks, providing a chronic intestinal inflammation model.  
Actually, there is no knowledge of a cure, so the treatment of IBD focuses on the use of 
drugs that decrease the inflammatory process and induce remission of the disease, in 
addition current therapies are not unanimously effective and result in various side 
effects [3,124 ].  In the last decade, the treatment of IBD has evolved considerably, with 
the appearance of several drugs directed to block specific inflammatory chain 
components sparking researchers’ interest in investigating the different drugs targeted 
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at a specific goal [25-27]. With this interest arises importance to study animal models of 
disease. Our study allowed create a TNBS-induced chronic colitis model with the main 
objective to provide a chronic pattern of intestinal inflammation disease to future 
pharmacological modulation with drugs like EPO, TDZD-8 and hemin. 
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Chapter 6 – Conclusion 
 
Experimental animal models have been developed and used for preclinical studies 
since they have contributed greatly to important advances in our current understanding 
of the immunological, pathological, and physiological features of chronic intestinal 
inflammation [83,91]. This animal model of colitis used in our study is an efficient 
method, since present clinical manifestations similar to those observed in human IBD 
and are capable of mimic the pattern of inflammation in human, producing a rapid, 
reliable and reproducible disease [6,83,94]. Animal model conclusions may provide 
vision into potential therapeutic approaches to ameliorate the inflammation and to 
minimize the morbidity and mortality associated with IBD [12,91,125]. However, careful 
attention may be required to translate animal studies to clinical settings by ensuring 
that both safety and efficacy can be achieved and robust clinical trials providing such 
potential benefits must be recommended before the use of these drugs for the 
management of IBD. Once the protocols of the TNBS-induced colitis model are not 
standardized, variability in the results in preclinical studies, due to several conditions 
such as type of induction method, administered doses and treatment period, difficult 
the translation of the data for the clinical practice, as well as the degree of disease and 
time required to produce the injury may vary between laboratories [84,85]. 
 
In the chronic TNBS-induced colitis model, colonic inflammation is induced in 
susceptible strains of mice, by intrarectal administrations of the haptenating substance, 
TNBS, in increasing doses, together with ethanol [8]. In our study, the development of a 
TNBS-induced colitis model was essential, as well as the standardization and 
validation of the induction method. Several conditions were tested to achieve a 
standard induction method, such as the dose of TNBS, the depth of TNBS 
administration, the time point for model evaluation, and the concentration of ethanol, as 
TNBS vehicle. The advantage of chronic models compared to acute models is that the 
latter may provide only limited information about the pathogenesis of human IBDs, as 
the chemical injury to the epithelial barrier leading to self-limiting inflammation rather 
than to chronic disease [125].  
 
The main objective established for this study was achieved. During this experiment, it 
was possible to develop a preliminary model of TNBS-induced chronic colitis. 
Throughout the induction method were evaluated and monitored several parameters, 
such as clinical signs, biochemical markers and concentration of pro- and anti-
inflammatory cytokines. All parameters under evaluation corroborated that the damage 
became chronic 4 weeks after the induction with TNBS 1% instillations. So, TNBS-
induced colitis was developed in 4 weeks, providing a chronic intestinal inflammation 
model. This model exhibits many of the pathological, molecular and immunological 
features of human colitis [8,126]. Additionally, the validation of this animal model is truly 
relevant to the scientific community, since there is no standard practice in the induction 
of colitis by TNBS. TNBS model can be a useful tool to study new metabolic pathways 
and new pharmacological approaches, consequently, facilitate a more effective and 
selective treatment than the currently known [127]. Supplementary experiments in the 
same research group were conducted in order to corroborate these findings. Upon 
these results, it is possible to propose a few topics for future development. Firstly, 
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analyze the data of histopathologic analysis of the bowel in order to assess the 
microscopic severity of colitis, allowing the evaluation of the extent of mucosal lesions 
in the collected tissues. Additionally, determine the concentration of IL-1β, a cytokine 
with a fundamental role in the pro-inflammatory immune response [128] and lastly, 
determine the myeloperoxidase activity, a specific biomarker of colonic oxidative stress 
[129]. 
  
In preclinical studies developed by our research group previously, was used 100 μL of 
2.5% TNBS in 50% ethanol to induce an acute TNBS-induced colitis model as a result 
of which the maximal damage was manifested on day 4. Furthermore, was observed a 
reduction of the inflammation associated with IBD after administration of erythropoietin, 
thiadiazolidinone-8, or hemin [25-27].  
 
Actually, and additional to findings of this work our research group propose to evaluate 
if all tested drugs previously in the acute model significantly inhibit chronic inflammatory 
response in this experimental chronic colitis model and if the efficacy and safety of 
these drugs are similar to comparing acute and chronic conditions. Some other 
interesting and promising examples of theoretically new strategies in IBD treatment 
include clarify the relevance of some changes in the drug delivery system and observe 
witch results that changes could promote in the therapeutic effect since topical 
application by rectal administration is eventually a good strategy to obtain a more 
effective and selective treatment with less adverse reactions.  
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